documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds registrants common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registranttable contents gilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item reserved part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences truvada viread hepsera ambisome emtriva vistide letairis volibris ranexa cayston atripla registered trademark belonging bristolmyers squibb gilead sciences llc lexiscan registered trademark belonging astellas us llc macugen registered trademark belonging eyetech inc sustiva registered trademark bristolmyers squibb pharma company tamiflu registered trademark belonging hoffmannla roche inc report also includes trademarks service marks trade names companiestable contents annual report including section entitled managements discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forward looking statements including statements regarding overall trends operating cost revenue trends liquidity capital needs statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forwardlooking statements various reasons including identified risk factors beginning given risks uncertainties cautioned place undue reliance forward looking statements forwardlooking statements included report made date hereof except required federal securities laws rules regulations securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise table contents part item business overview gilead sciences inc gilead us incorporated delaware june biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need mission advance care patients suffering life threatening diseases worldwide headquartered foster city california operations north america europe asia pacific date focused efforts bringing novel therapeutics treatment life threatening diseases market continue seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategy products atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oral formulation dosed day treatment human immunodeficiency virus hiv infection adults atripla first oncedaily singletablet regimen hiv intended stand alone therapy combination antiretrovirals fixeddose combination antiretroviral medications viread tenofovir disoproxil fumarate emtriva emtricitabine bristol myerssquibb companys bms nonnucleoside reverse transcriptase inhibitor sustiva efavirenz truvada emtricitabine tenofovir disoproxil fumarate oral formulation dosed day part combination therapy treat hiv infection adults fixeddose combination antiretroviral medications viread emtriva viread oral formulation nucleotide analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults received marketing approval viread treatment chronic hepatitis b licensed glaxosmithkline inc gsk rights commercialize viread treatment chronic hepatitis b china japan saudi arabia emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults united states europe emtriva also approved part combination therapy treat hiv infection children hepsera adefovir dipivoxil oral formulation nucleotide analogue polymerase inhibitor dosed day treat chronic hepatitis b licensed gsk rights commercialize hepsera treatment chronic hepatitis b asia latin america certain territories ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat serious invasive fungal infections caused various fungal species corporate partner astellas pharma us inc promotes sells ambisome united states canada promote sell ambisome europe australia new zealand letairis ambrisentan endothelin receptor antagonist era indicated treatment pulmonary arterial hypertension pah group patients class ii iii symptoms improve exercise capacity delay clinical worsening sublicensed gsk rights ambrisentan marketed gsk volibris ambrisentan pah territories outside united states ranexa ranolazine indicated treatment chronic angina licensed menarini international operations luxembourg sa rights ranexa territories outside united states vistide cidofovir injection antiviral medication treatment cytomegalovirus retinitis patients aids table contents cayston aztreonam inhalation solution inhaled antibiotic treatment improve respiratory systems cystic fibrosis cf patients pseudomonas aeruginosa p aeruginosa september received conditional marketing approval cayston europe canada february received marketing approval cayston united states following table lists aggregate product sales major products thousands total total total product product product sales sales sales antiviral products atripla truvada viread hepsera emtriva total antiviral products ambisome letairis ranexa total product sales see item note consolidated financial statements included annual report total revenues geographic area royalties products tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu approved treatment influenza children adults countries including united states japan european union tamiflu also approved prevention influenza children adults united states japan european union developed tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us royalties based percentage net sales tamiflu macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelated macular degeneration macugen developed eyetech inc eyetech using technology licensed us promoted united states eyetech eyetech holds exclusive rights manufacture sell macugen united states pfizer inc pfizer holds exclusive right manufacture sell macugen rest world receive royalties eyetech based sales macugen worldwide lexiscanrapiscan regadenoson injection indicated use pharmacologic stress agent radionuclide myocardial perfusion imaging mpi test detects characterizes coronary artery disease patients unable undergo adequate exercise stress astellas us llc exclusive rights manufacture sell regadenoson name lexiscan united states subject obligations pay us royalties based sales lexiscan united states september marketing authorization application regadenoson mpi european union approved european medicines agency rapidscan pharma solutions inc rapidscan holds exclusive right manufacture sell regadenoson name rapiscan europe certain territories outside united states receive royalties rapidscan sales territories table contents commercialization distribution products marketed commercial teams andor conjunction thirdparty distributors corporate partners commercial teams promote products direct field contact physicians hospitals clinics healthcare providers generally grant thirdparty distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory us international commercial sales operations marketing subsidiaries australia austria belgium canada denmark finland france germany greece ireland italy netherlands new zealand norway poland portugal spain sweden switzerland turkey united kingdom united states united states commercial team promotes truvada viread emtriva hepsera letairis ranexa promote atripla united states joint venture partner bms distribute atripla truvada viread emtriva hepsera vistide ranexa united states exclusively wholesale channel product sales three large wholesalers cardinal health inc mckesson corp amerisourcebergen corp accounted total revenues years ended december combined basis wholesalers accounted approximately product sales united states approximately total worldwide revenues corporate partner astellas promotes sells distributes ambisome lexiscan us united states cayston letairis distributed exclusively specialty pharmacies specialty pharmacies specialize dispensing medications complex chronic conditions may require high level patient education ongoing counseling sell distribute truvada viread emtriva hepsera ambisome asia australia europe latin america middle east new zealand either commercial teams thirdparty distributors corporate partners promote atripla jointly bms majority countries europe responsible selling distributing product countries limited number central eastern european countries either gilead bms third party distributor sole promoting selling distributing company agreement merck co inc merck promote distribute atripla countries latin america asia pacific either merck existing thirdparty distributors gsk promotes sells distributes hepsera asia latin america certain territories plans promote sell distribute viread treatment chronic hepatitis b china japan saudi arabia rely corporate partner japan tobacco inc promote sell truvada viread emtriva japan corporate partner astellas promotes sells distributes ambisome canada dainippon sumitomo pharma co ltd responsible promotion distribution ambisome japan menarini international operations luxembourg sa markets ranexa certain territories outside united states treatment chronic angina rapidscan pharma solutions inc markets rapiscan regadenoson certain territories outside united states inducement pharmacological stress andor vasodilation coronary vasculature strictly purposes diagnosing cardiovascular disease access developing world gilead access program established certain hiv products available substantially reduced prices countries developing world developed system tiered pricing reflects economic status using gross national income per capita gni hiv prevalence approach allows us price therapies based countrys ability pay also support many clinical studies donation products help define best treatment strategies developing world countries example november entered collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection clinical study conducted mrc antiretroviral hiv therapy africa table contents trial called dart development antiretroviral therapy study aimed studying clinical versus laboratory monitoring practices structured treatment interruptions continuous antiretroviral therapy adults hiv infection subsaharan africa provided viread cost dart study addition donated tenofovir centre aids programme research south africa caprisa microbicide trial assessed effectiveness safety tenofovirbased microbicide gel prevention hiv infection south african women also provide drugs number innovative international studies investigating whether viread truvada prevent hiv transmission among atrisk uninfected adults potential hiv prevention strategy called preexposure prophylaxis prep also work closely world health organization nongovernmental organizations provide ambisome treatment leishmaniasis parasitic disease preferential price resource limited settings support numerous clinical studies investigating role ambisome treat visceral cutaneous leishmaniasis developing countries collaborations organizations drugs neglected diseases initiative mdecins sans frontires also entered number collaborations related access products developing world include pharmachem technologies grand bahama ltd pharmachem pharmachem one commercial manufacturing partners established facility bahamas manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread one active pharmaceutical ingredients atripla truvada resource limited countries cooperative effort pharmachem grand bahama port authority aspen pharmacare holdings ltd aspen october entered nonexclusive manufacturing distribution agreement aspen providing manufacture distribution viread truvada treatment hiv infection certain developing world countries included gilead access program november amended agreement aspen amended agreement aspen retained right manufacture distribute viread truvada treatment hiv infection developing world countries aspen right purchase viread truvada unlabeled bottles us distribution countries also right manufacture viread truvada using active pharmaceutical ingredient purchased aspen suppliers approved us aspen also granted right manufacture distribute generic versions emtricitabine tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination emtricitabine treatment hiv infection aspen required pay us royalties net sales viread truvada well royalties net sales generic versions tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination generic versions emtricitabine manufactured distributed aspen generic licenses entered nonexclusive license agreements thirteen indian generic manufacturers granting rights produce distribute generic versions tenofovir disoproxil fumarate treatment hiv infection low income countries around world includes india many low income countries gilead access program agreements require generic manufacturers meet certain national international regulatory standards include technology transfers enable expeditious production large volumes high quality generic versions tenofovir disoproxil fumarate addition agreements allow manufacture commercial quantities active pharmaceutical ingredient finished product merck co inc august entered agreement affiliate merck pursuant gilead merck provide atripla substantially reduced prices hiv infected patients developing countries africa caribbean latin america southeast asia agreement manufacture atripla using efavirenz supplied merck merck handles distribution product countries covered agreement table contents international partnership microbicides ipm conrad december entered agreement granted rights ipm conrad cooperating agency us agency international development committed improving reproductive health expanding contraceptive choices women men develop manufacture proven efficacious arrange distribution resource limited countries certain formulations tenofovir use topical microbicide prevent hiv infection competition products target number areas including viral fungal respiratory cardiovascular diseases many commercially available products treatment diseases many companies institutions making substantial investments developing additional products treat diseases products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv products hiv landscape becoming competitive complex treatment trends continue evolve growing number antihiv drugs currently sold advanced stages clinical development approximately branded hiv drugs available united states products primarily compete fixeddose combination products nucleotidenucleoside reverse transcriptase inhibitors nrti class including combivir lamivudinezidovudine epzicomkivexa abacavirlamivudine trizivir abacavirlamivudinezidovudine sold joint venture established november gsk pfizer focused hiv therapies hiv products also compete broadly hiv products abbott laboratories inc boehringer ingelheim gmbh merck roche tibotec pharmaceuticals bmss videx ec didanosine ddi became first generic hiv product united states gsks retrovir zidovudine also faces generic competition united states result launch generic zidovudine bmss zerit stavudine also faces generic competition united states result launch generic stavudine date little impact generic didanosine zidovudine stavudine price hiv products however price decreases hiv products may result longer term lamivudine marketed joint venture established gsk pfizer competitive emtricitabine active pharmaceutical ingredient emtriva component atripla truvada may compound patent covering epivir lamivudine expired united states expect see generic lamivudine united states near future generic lamivudine available spain since march expect generic versions lamivudine launched countries within european union early first quarter table contents hbv products hepatitis b virus hbv products hepsera viread face significant competition existing expected therapies treating patients chronic hepatitis b hbv products face competition baraclude entecavir oral nucleoside analogue developed bms launched united states tyzekasebivo telbivudine oral nucleoside analogue developed novartis pharmaceuticals corporation novartis sale united states european union china hbv products also compete epivirhbvzeffix lamivudine developed gsk collaboration shire pharmaceuticals group plc sold major countries throughout north south america europe asia hepsera viread treatment chronic hepatitis b also compete established immunomodulatory therapies including introna interferon alfab sold schering plough corporation major countries throughout north south america europe asia pegasys pegylated interferon alfaa injectable drug similar introna sold roche treatment chronic hepatitis b cardiovascular products letairis competes directly tracleer bosentan sold actelion pharmaceuticals us inc actelion indirectly pah product united therapeutics corporation ranexa competes predominantly generic compounds three distinct classes drugs treatment chronic angina united states including generic andor branded betablockers calcium channel blockers longacting nitrates addition surgical treatments interventions coronary artery bypass grafting percutaneous coronary intervention another option angina patients may perceived healthcare practitioners preferred methods treat cardiovascular disease underlies causes angina united states numerous marketed generic andor branded pharmacologic stress agents compete lexiscan clinical data inc developing apadenoson pharmacologic stress agent mpi currently phase clinical trials stress agents product candidates could also compete lexiscan products ambisome faces strong competition several current expected competitors competition current expected competitors may erode revenues receive sales ambisome ambisome faces competition vfend voriconazole developed pfizer caspofungin product developed merck marketed cancidas united states caspofungin elsewhere ambisome also competes lipidbased amphotericin b products including abelcet amphotericin b lipid complex injection sold enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sold three rivers pharmaceuticals llc worldwide anfogen amphotericin b liposomal sold genpharma sa argentina bms numerous generic manufacturers sell conventional amphotericin b also competes ambisome aware least two lipid formulations claim similarity ambisome becoming available outside united states including possible entry one formulation greece formulations may reduce market demand ambisome manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association table contents vistide competes number drugs also treat cytomegalovirus retinitis including cytovene iv cytovene ganciclovir sold intravenous oral formulations roche ocular implant bausch lomb incorporated valcyte valganciclovir also marketed roche foscavir foscarnet intravenous drug sold astrazeneca plc vitravene fomivirsen drug injected directly eye sold cibavision cayston competes primarily tobi tobramycin inhalation solution usp inhaled medication sold novartis treatment cf patients whose lungs contain p aeruginosa tamiflu competes relenza zanamivir antiinfluenza drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder generic competitors include amantadine rimantadine oral tablets inhibit replication influenza virus biocryst pharmaceuticals inc developing injectable formulations peramivir influenza neuraminidase inhibitor treatment influenza currently phase clinical trials macugen competes primarily visudyne verteporfin injection sold novartis used connection photodynamic therapy lucentis ranibizumab sold genentech inc number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs collaborative relationships part business strategy establish collaborations companies universities medical research institutions assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring products rights products technologies complementary business companies universities medical research institutions information regarding certain relationships including ongoing financial accounting impact business found item note consolidated financial statements included annual report commercial collaborations although currently number collaborations corporate partners govern manufacture sale distribution andor marketing products various territories worldwide following commercial collaborations significant us financial statement perspective significant ongoing collaboration activity exists roche september entered development license agreement roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche original agreement roche exclusive right obligation manufacture sell tamiflu worldwide subject obligation pay us percentage net sales roche generated tamiflu sales agreement received upfront payment amount million entitled receive additional milestone payments million upon achievement certain development regulatory objectives received milestone payments october roche also made cash payment us amount million related reimbursement certain research preclinical development expenses obligation table contents prosecute maintain certain patents agreement november entered first amendment supplement original agreement roche amendment eliminated cost goods adjustments royalty calculation retroactive calendar year future calculations amendment also provided formation joint manufacturing committee review roches manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis committees consists representatives roche us amendment option provide specialized sales force supplement roches us marketing efforts tamiflu exercised date agreement roches obligation pay royalties us terminate countrybycountry basis patents providing exclusivity tamiflu countries expire roche may terminate agreement reason case rights tamiflu would revert us either party may terminate agreement response material breach party bms december entered collaboration bms develop commercialize singletablet regimen truvada bmss sustiva united states combination approved use united states july sold brand name atripla bms structured collaboration joint venture forming limited liability company called bristolmyers squibb gilead sciences llc terms collaboration bms granted royalty free sublicenses joint venture use respective company owned technologies return granted license joint venture use intellectual property results collaboration economic interests joint venture held us bms including share revenues outofpocket expenses based portion net selling price atripla attributable truvada sustiva respectively since net selling price truvada may change time relative net selling price sustiva bmss respective economic interests joint venture may vary annually bms share marketing sales efforts parties providing equivalent sales force efforts levels agreed annually bms gilead starting second quarter except limited number activities jointly managed parties longer coordinate detailing promotional activities united states parties continue collaborate activities manufacturing regulatory compliance pharmacovigilance daily operations joint venture governed four primary joint committees formed bms gilead responsible accounting financial reporting tax reporting product distribution joint venture september bms amended joint ventures collaboration agreement allow joint venture sell atripla canada agreement continue terminated mutual agreement parties addition either party may terminate partys participation collaboration within days launch least one generic version partys single agent products double agent products nonterminated party right continue sell atripla shortterm obligation pay royalties terminated party december entered collaboration bms sets forth terms conditions bms commercialize atripla european union iceland liechtenstein norway switzerland either bms thirdparty distributor act selling party countries responsible among things receiving processing customer orders warehousing product collecting receivables handling returns manufacturing atripla coordinated us primarily responsible distribution logistics general parties share revenues outofpocket expenses proportion net selling prices truvada respect us efavirenz respect bms agreement terminate upon expiration lasttoexpire patent affords market exclusivity atripla one components european countries covered agreement prior time either party may terminate agreement reason termination effective december nonterminating party right continue sell atripla obligated pay table contents terminating party certain royalties three year period following effective date termination event nonterminating party decides sell atripla effective date termination date atripla withdrawn country date third party assumes distribution atripla whichever earlier gsk march sublicensed gsk exclusive rights market ambrisentan active pharmaceutical ingredient letairis name volibris pah territories outside united states license agreement received upfront payment million subject achievement specific milestones eligible receive total additional milestone payments million december received million potential milestone payments addition receive royalties based net sales volibris gsk territories gsk option negotiate us exclusive sublicense additional therapeutic uses volibris gsk territories term license agreement agreement continue conduct bear expense clinical development activities believe required obtain maintain regulatory approvals letairis volibris united states canada european economic area party may conduct additional development activities territories expense parties may agree jointly develop ambrisentan new indications licensed field party pay share external costs associated joint development agreement gsks obligation pay royalties us terminate countrybycountry basis earlier date generic equivalents sold country achieve certain percentage total prescriptions product plus generic equivalents fifteenth anniversary commercial launch country gsk may terminate agreement reason upon termination rights product would revert us either party may terminate agreement response material breach party research collaborations currently number collaborations corporate partners govern research development rd certain compounds drug candidates following research collaborations significant us financial statement perspective significant ongoing collaboration activity exists japan tobacco inc japan tobacco march entered licensing agreement japan tobacco japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco would retain rights agreement responsible seeking regulatory approval territories required use diligent efforts commercialize product treatment hiv infection bear costs expenses associated commercialization efforts terms agreement paid upfront license fee million obligated make total potential milestone payments million upon achievement certain clinical regulatory commercial objectives additionally obligated pay royalties based net sales territories market product december made total milestone payments million agreement obligation pay royalties japan tobacco terminate productbyproduct basis patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement reason case license granted japan tobacco us would terminate either party may terminate agreement response material breach party tibotec pharmaceuticals tibotec july entered license collaboration agreement tibotec whollyowned subsidiary johnson johnson develop commercialize fixeddose combination truvada tibotecs nonnucleoside reverse transcriptase inhibitor tmc mg rilpivirine hydrochloride agreement tibotec granted us exclusive license combination product administration adults table contents oncedaily oral dosage form worldwide excluding developing world countries japan neither party restricted combining drugs drugs reimburse tibotec million tibotecs development costs tmc required use commercially reasonable efforts develop formulate combination product including completion bioequivalence studies december recorded million approximately million reimbursable rd expenses incurred tibotec development tmc tibotec required use commercially reasonable efforts develop tmc obtain approval united states europe manufacture combination product assume lead role registration distribution subject regulatory approval commercialization combination product licensed countries tibotec right detail combination product licensed countries option request distributor combination product limited number countries price combination product expected sum prices truvada tmc components cost tmc purchased us tibotec combination product approximate market price tmc less specified percentage thirty percent either party may terminate agreement combination product withdrawn market party materially breaches agreement certain clinical regulatory conditions met may terminate agreement united states canada expiration lasttoexpire patent tenofovir disoproxil fumarate united states may terminate agreement country expiration lasttoexpire patent tenofovir disoproxil fumarate country european union tibotec may terminate agreement united states canada expiration lasttoexpire patent tmc united states may terminate agreement country expiration lasttoexpire patent tmc country european union research development product development efforts cover wide range medical conditions including hivaids liver disease cardiovascular disease respiratory disease research scientists foster city palo alto san dimas california branford connecticut seattle washington engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs summary key product candidates corresponding current stages development additional information development pipeline visit website wwwgileadcom table contents product candidates treatment hiv product candidates description marketing application pending truvadatmc september announced submitted new drug application european medicines singletablet regimen agency marketing approval singletablet regimen tenofovir disoproxil fumarate emtricitabine tmc treatment hivaids treatmentnaive patients november submitted new drug application us food drug administration fda singletablet regimen january received refuse file notification fda regarding application fda requested additional information respect chemistry manufacturing controls section application february refiled new drug application included requested information awaiting fdas response whether substantially complete permit substantive review phase cobicistat cobicistat pharmacoenhancer evaluation boosting agent certain hiv medicines treatmentnave patients elvitegravir elvitegravir oral integrase inhibitor evaluated part combination therapy hiv treatmentexperienced patients integrase singletablet oncedaily singletablet quad regimen elvitegravir cobicistat tenofovir disoproxil fumarate regimen quad emtricitabine evaluation treatment hivaids treatmentnave patients phase gs gs nucleotide reverse transcriptase inhibitor evaluated treatment hivaids product candidates treatment liver diseases product candidates description phase gs gs oral nsb nonnucleoside polymerase inhibitor evaluated treatment hepatitis c gs gs ns oral protease inhibitor evaluated treatment hepatitis c gs gs oral ns protease inhibitor evaluated treatment hepatitis c phase gs gs oral nsa inhibitor evaluation treatment hepatitis c gs gs oral nucleotide nsb polymerase inhibitor evaluation treatment hepatitis c gs gs oral tlr agonist treatment hepatitis b hepatitis c table contents product candidates treatment cardiovascularmetabolic diseases product candidates description phase cicletanine cicletanine oral antihypertensive agent evaluation treatment pah ranolazine ranolazine late sodium current inhibitor approved treatment chronic angina also evaluated treatment coronary artery disease patients diabetes product candidates treatment respiratory diseases product candidates description phase aztreonam aztreonam inhalation solution approved treatment cystic fibrosis cf patients inhalation solution pseudomonas aeruginosa also evaluated treatment cf patients burkholderia spp phase aztreonam aztreonam inhalation solution also evaluated treatment bronchiectasis inhalation solution product candidates treatment inflammationoncology diseases product candidates description phase gs gs monoclonal antibody evaluated treatment idiopathic pulmonary fibrosis solid tumors total rd expenses billion compared million million addition internal discovery clinical development programs seek add portfolio products product acquisitions following table shows recent acquisitions year company therapeutic area myogen inc cardiopulmonary disease cardiovascular disorders corus pharma inc respiratory infectious diseases navitas assets llc cicletanine potential treatment pah cv therapeutics inc cardiovascular disorders cgi pharmaceuticals inc serious inflammatory diseases arresto biosciences inc fibrotic diseases cancer february entered agreement acquire calistoga pharmaceuticals inc privatelyheld biotechnology company focused development medicines treat cancer inflammatory diseases table contents patents proprietary rights us european patent expiration number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows actual estimated expiration dates united states europe primary patents patents may issue pending applications cover compounds marketed products us patent european patent products expiration expiration vistide hepsera letairis ambisome tamiflu macugen viread ranexa lexiscan emtriva truvada atripla cayston supplementary protection certificate spc protection obtained certain european countries confer auxiliary form patent exclusivity spc protection obtained certain european countries confer auxiliary form patent exclusivity patent term extension applied spc applied upon marketing approval european union based european patent expiration date viread one components truvada based european patent expiration date viread one components atripla application allowed spc applied upon grant european patent patent protection certain challenges patents proprietary rights important business properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy patents covering active pharmaceutical ingredients atripla truvada viread emtriva hepsera letairis vistide lexiscan held third parties acquired exclusive rights patents agreements parties patents cover ranolazine active ingredient ranexa instead discovered sustained release formulation ranolazine would achieve therapeutic plasma table contents levels patents obtained formulations characteristic plasma levels achieve patents cover active ingredients ambisome instead hold patents liposomal formulations compound also protect formulations trade secrets addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hepatitis b indication hepsera developed may obtain patents certain products many years obtain marketing approval products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions example extensions patents many products granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third parties allow us use technology certain required could obtain license thirdparty technology could obtain one reasonable cost able obtain required license alternative technologies may unable develop commercialize products business could adversely affected example aware body patents may relate operation letairis education access program leap restricted distribution program designed support letairis patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents competitors file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful results operations may adversely affected participation events patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation examination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection example public patent foundation filed requests reexamination united states patent trademark office pto challenging four patents related tenofovir disoproxil tenofovir disoproxil fumarate active pharmaceutical ingredient atripla truvada viread pto granted requests issued nonfinal rejections four patents step common proceeding initiate reexamination process pto confirmed patentability four patents although successful responding pto actions instance similar organizations may still challenge patents foreign jurisdictions example april brazilian health ministry citing us patent reexamination proceedings grounds rejection requested brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issued final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate filed brazil filed appeal within patent authority responding questions raised rejection july brazilian patent authority rejected application highest level appeal available us table contents within brazilian patent authority filed civil action brazilian federal court appeal action brazilian patent authority predict outcome proceeding tenofovir disoproxil fumarate patent application unsuccessful appeal courts decision patent authority brazilian government would likely purchase generic tenofovir disoproxil fumarate would significantly reduce sales hiv products brazil brazilian government purchased approximately million hiv products aware applications two generic companies sell generic version viread brazil one generic applicants able compete contract would expect brazilian government purchase hiv products another example patent office india initially allowed claims covering tenofovir disoproxil tenofovir disoproxil fumarate however indian civil procedure prior official grant allowed applications several parties filed legal actions protest decision grant patents august indian patent office announced decided actions us would therefore allow patents granted filed appeal within indian patent office intellectual property appellate board applications predict outcome proceedings unsuccessful appeal decisions appeals pursued indian court system may ultimately prove unsuccessful meantime competitor able sell generic tenofovir disoproxil fumarate india addition unsuccessful appealing negative decisions indian patent office indian courts competitors would able continue sell generic tenofovir disoproxil fumarate could reduce amount royalties receive indian generic licenses pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products closely related developed developing addition certain countries africa asia including china provide effective enforcement patents thirdparty manufacturers able sell generic versions products countries abbreviated new drug applications filed generic manufacturers part approval process products us food drug administration fda granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products addition generic manufacturers sought may continue seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug example november received notice teva pharmaceuticals teva submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic version atripla notice teva challenged two emtricitabine patents may filed another lawsuit teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir disoproxil fumarate patents protecting viread january also received notices teva amending andas related atripla truvada notice related truvada teva challenged four table contents patents related tenofovir disoproxil fumarate two additional patents related emtricitabine notice related atripla teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine two patents related efavirenz march filed lawsuit teva infringement four viread patents two additional emtricitabine patents march bms merck filed lawsuit teva infringement patents related efavirenz june received notice lupin limited lupin submitted anda fda requesting permission manufacture market generic version ranexa notice lupin alleges ten patents associated ranexa invalid unenforceable andor infringed lupins manufacture use sale generic version ranexa july filed lawsuit lupin infringement patents ranexa august received notice sigmapharm labs sigmapharm submitted anda fda requesting permission manufacture market generic version hepsera notice sigmapharm alleges patents associated hepsera invalid unenforceable andor infringed sigmapharms manufacture use sale generic version hepsera september filed lawsuit sigmapharm infringement patents hepsera one patents challenged sigmapharm also challenged ranbaxy inc ranbaxy pursuant notice received october patent challenged ranbaxy expires july considering options enforcing patent february received notice natco pharma limited natco submitted anda fda requesting permission manufacture market generic version tamiflu notice natco alleges patent associated tamiflu invalid unenforceable andor infringed natcos manufacture use sale generic version tamiflu currently reviewing notice letter days date receipt commence patent infringement lawsuit natco predict ultimate outcome actions may spend significant resources enforcing patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states could substantially shortened patents covering products invalidated fda could approve requests manufacture generic version products prior expiration date patents trade secrets also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions table contents manufacturing raw materials manufacturing strategy contract third parties manufacture majority active pharmaceutical ingredients solid dose products also rely corporate partners manufacture certain products additionally manufacturing facilities san dimas california edmonton alberta canada cork ireland manufacture certain products active pharmaceutical ingredients clinical commercial uses manufacturing products contract third parties manufacture certain products clinical commercial purposes including atripla truvada viread emtriva hepsera ranexa vistide cayston use multiple thirdparty contract manufacturers manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread one active pharmaceutical ingredients atripla truvada emtricitabine active pharmaceutical ingredient emtriva one active pharmaceutical ingredients atripla truvada rely single thirdparty manufacturer manufacture active pharmaceutical ingredients ranexa cayston process validating second manufacturer ranexa cayston also rely thirdparty contract manufacturers tablet capsulate products example use multiple thirdparty contract manufacturers tablet atripla truvada viread hepsera ranexa emtriva capsulation also completed thirdparty contract manufacturers rely single thirdparty supplier manufacture emtriva capsules letairis tablets also manufacturing agreements many corporate partners roche third parties responsible manufacturing tamiflu agreement roche joint manufacturing committee composed representatives roche us opportunity review roches existing manufacturing capacity tamiflu global plans manufacturing tamiflu astellas us llc corporate partner lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan pari pharma gmbh responsible manufacturing device required administer cayston lungs patients device made single supplier single site future products continue consider developing additional manufacturing capabilities establishing additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future products ability conduct large scale clinical trials meet customer demand commercial products adversely affected manufacturing facilities san dimas facility manufacture fill package products manufacture ambisome cayston exclusively facility depend single supplier high quality cholesterol used manufacture ambisome fill finish macugen exclusively facilities san dimas manufacturing agreements eyetech pfizer eyetech currently provides us pegaptanib sodium active pharmaceutical ingredient macugen also fill package drug product atripla truvada viread emtriva hepsera ranexa finished forms facilities san dimas event disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome cayston macugen meet market needs edmonton alberta facility carry process research scaleup clinical development candidates manufacture active pharmaceutical ingredients investigational commercial products table contents conduct chemical development activities improve existing commercial manufacturing processes addition utilize site manufacture emtricitabine also manufacture active pharmaceutical ingredients vistide letairis hepsera exclusively edmonton site although another supplier qualified make active pharmaceutical ingredient letairis fill package drug product atripla truvada viread emtriva cayston hepsera finished forms facilities cork ireland also perform quality control testing final labeling packaging ambisome final release many products european union elsewhere facility utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral products well product packaging activities distribute products european union international markets dublin ireland site thirdparty manufacturers thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected believe technology use manufacture products proprietary products manufactured thirdparty contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements thirdparty manufacturers intended restrict manufacturers using revealing technology certain thirdparty manufacturers comply restrictions addition thirdparty manufacturers could develop technology related work perform us may need manufacture products could required enter additional agreements thirdparty manufacturers want use technology allow another manufacturer use technology thirdparty manufacturer could refuse allow us use technology could demand terms use technology acceptable us regulation manufacturing process manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations thirdparty manufacturers corporate partners subject current good manufacturing practices extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda european medicines agency similar regulations effect countries january february fda conducted routine inspection san dimas california manufacturing distribution facility manufacture ambisome cayston fill finish macugen package solid dosage form products conclusion inspection fda issued form inspectional observations stating concerns maintenance aseptic processing conditions manufacturing suite ambisome product environmental maintenance issues san dimas warehousing facility batch sampling timeliness completion annual product quality reports september san dimas manufacturing facility received warning letter fda detailing fdas concerns ambisome manufacturing environment including control systems monitoring procedures prevent microbiological contamination preventative cleaning equipment maintenance referencing certain viread lots letter also stated concerns connected quality procedures controls investigation procedures generalized concern effectiveness san dimas quality unit carrying responsibilities table contents november december fda reinspected san dimas facility reinspection closed additional form observations consequently believe addressed fdas concerns stated form observations warning letter awaiting confirmation acceptance fda unless receive confirmation fda satisfied corrected outstanding issues fda may withhold permission export ambisome cayston manufactured san dimas certain countries outside united states europe fda may also withhold approval pending drug applications listing san dimas facility since required notified appropriate international regulatory authorities letters issuance possible letter may impact ability supply aseptic products manufactured san dimas ambisome cayston macugen outside united states result warning letter unable receive export regulatory approvals ambisome products issue may unable sell sufficient quantities products meet market demand would decrease revenues harm business believe warning letter impact ability supply solid dosage form products package san dimas facility include atripla truvada viread emtriva hepsera letairis ranexa event solid dosage form products affected alternate sites could supply products access supplies materials need access certain supplies products manufacture products delivery material suppliers interrupted reason unable purchase sufficient quantities raw materials used manufacture products may unable ship certain products commercial supply supply product candidates development clinical trials example significant portion raw materials intermediates used manufacture hiv products atripla truvada viread emtriva supplied chinesebased companies result international trade dispute china united states actions chinese government would limit prevent chinese companies supplying materials would adversely affect ability manufacture supply hiv products meet market needs material adverse effect operating results seasonal operations backlog worldwide product sales reflect significant degree seasonality however royalty revenues represented total revenues consisted primarily tamiflu royalties affected seasonality royalty revenue recognize roches sales tamiflu impacted severity flu seasons product delivery response hn influenza pandemic part operate markets characterized short lead times absence significant backlogs believe backlog information material business whole government regulation operations activities subject extensive regulation numerous government authorities united states countries united states drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming fda must approve drug sold united states general process approval follows table contents preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidates potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts investigational new drug application drug candidate studied human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous phase clinical trials phase drug candidate appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials fda approval process believe data phase clinical trials show adequate level safety efficacy submit appropriate filing usually form new drug application nda supplemental nda fda seeking approval sell drug candidate particular use fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees compound met required level safety efficacy particular use allow us sell drug candidate united states use unusual however fda reject application believes drug candidate safe enough efficacious enough believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval table contents addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california including san dimas facilities also must licensed state california compliance local regulatory requirements manufacturing facilities located canada including edmonton alberta facility facilities located near dublin cork ireland also must obtain local licenses permits compliance local regulatory requirements drugs treat serious life threatening diseases conditions adequately addressed existing drugs development program designed address unmet medical need may designated fast track candidates fda may eligible accelerated priority review drugs treatment hiv infection designated use us presidents emergency plan aids relief may also qualify expedited priority review viread truvada atripla received accelerated approval priority reviews drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union includes major countries europe centralized approval procedure used approval one country european union used obtain approval another country european union one two simplified application processes mutual recognition procedure decentralized procedure rely principle mutual recognition receiving regulatory approval european registration procedures separate pricing reimbursement approvals also required countries pricing reimbursement successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services particularly new innovative products therapies resulted lower average selling prices addition changes rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement policies pricing general may adversely affect product revenues profitability legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states significant changes federal medicare system recent years united states could impact pricing products medicare prescription drug improvement modernization act medicare beneficiaries able elect coverage prescription drugs medicare part prescription drug program began january although benefited patients transitioning medicaid medicare part since longer term impact medicare part business clear impact depend part specific decisions regarding level coverage provided therapeutic categories products included terms coverage provided extent preference given selected products category thirdparty payers providing medicare part coverage attempted negotiate price concessions pharmaceutical manufacturers addition discussions taking place federal level pass legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare pricing table contents increasing pressure lower prescription drug prices may limit drug access medicare part enrollees medicare patients pay coinsurance may influence products recommended physicians selected patients addition federal medicare proposals state medicaid drug payment changes could also lower payment products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules europe success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many european countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization months reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates revenuerelated taxes profit control expect prices prescription pharmaceuticals decline life product volumes increase recently many countries european union increased amount discounts required products efforts could continue countries attempt manage healthcare expenditures especially light severe fiscal debt crises experienced many countries european union example june spain imposed incremental discount branded drugs august germany increased rebate prescription pharmaceuticals countries recently imposed could impose similar discounts products generic drugs come market may face price decreases products countries european union government agencies also issue regulations guidelines directly applicable us products addition time time professional societies practice management groups private healthscience foundations organizations publish guidelines recommendations directed certain health care patient communities recommendations guidelines may relate matters product usage dosage route administration use related competing therapies consequently result increased decreased usage products example recent hiv treatment guidelines united states abroad endorsed earlier diagnosis treatment united states healthcare reform march healthcare reform legislation adopted united states result required rebate discount products reimbursed paid various public payers including medicaid entities eligible purchase discounted products b drug pricing program public health service act aids drug assistance programs adaps discounts rebates fees legislation impacted us include effective january minimum base rebate amount owed medicaid products reimbursed medicaid increased discounts rebates owe adaps public health service entities reimburse purchase products also increased effective march required extend rebates patients receiving products medicaid managed care organizations effective january required provide discount products sold patients medicare part donut hole effective along pharmaceutical manufacturers branded drug products required pay portion new industry fee also known pharmaceutical excise tax calculated based select government sales calendar year percentage total industry government sales table contents starting number people access healthcare coverage expected increase could experience positive impact sales products expansion healthcare coverage may decrease reliance patients state adaps currently rely availability federal state funding full impact healthcare reform reduction approximately million us net product sales majority impact began third quarter continued throughout fourth quarter since new discount rebate requirements took two quarters fully take effect excluding impact new pharmaceutical excise tax estimate impact healthcare reform product sales approximately us net product sales many specific determinations necessary implement healthcare reform legislation yet decided communicated federal government example know many quickly patients receiving product medicare part program reach donut hole details pharmaceutical excise tax calculated based information date estimate impact pharmaceutical excise tax million classified selling general administrative sga expense excise tax tax deductible calculating anticipated financial impacts healthcare reform described made several estimates assumptions respect expected payer mix reforms implemented health care fraud abuse laws subject various federal state laws pertaining health care fraud abuse including antikickback laws false claims laws antikickback laws make illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business including purchase prescription particular drug due breadth statutory provisions increasing attention given law enforcement authorities possible certain practices may challenged antikickback similar laws false claims laws prohibit anyone knowingly willingly presenting causing presented payment thirdparty payers including medicare medicaid claims reimbursed drugs services false fraudulent claims items services provided claimed claims medically unnecessary items services sales marketing activities may subject scrutiny laws violations fraud abuse laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid government allege convict us violating laws could material adverse effect results operations compulsory licenses number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread july brazilian patent authority rejected patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread highest level appeal available us within brazilian patent authority filed civil action brazilian federal court appeal action brazilian patent authority unable successfully appeal decision patent authority courts brazilian government would likely purchase generic tenofovir disoproxil fumarate would significantly reduce sales hiv products brazil brazilian government purchased approximately million hiv products aware applications two generic companies sell generic version viread brazil one table contents generic applicants able compete contract would expect brazilian government purchase hiv products addition concerns cost availability tamiflu related potential avian flu hn influenza pandemic generated international discussions compulsory licensing tamiflu patents example canadian government may allow canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canadas access medicines regime furthermore roche issued voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit thirdparty manufacturing tamiflu developments could reduce royalties receive roches sales tamiflu certain countries permit enforcement patents thirdparty manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales employees january approximately fulltime employees believe good relations employees environment health safety seek comply applicable statutory administrative requirements concerning environmental quality worker health safety made continue make expenditures environmental compliance protection expenditures expected material effect capital expenditures results operations competitive position voluntarily assessing greenhouse gas emissions begun take action reduce emissions example establishing employee commuter programs evaluating energy efficiency buildings various laws regulations implemented consideration mitigate effects climate change caused greenhouse gas emissions example california air resources board process drafting regulations meet state emissions targets based current information subject finalization proposed regulations believe primary risk related climate change risk increased energy costs however energy intensive business anticipate subject cap trade system mitigation measures would likely material capital expenditures results operations competitive position also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds rd activities eliminate risk accidental contamination injury materials certain misuse accidents involving materials could lead significant litigation fines penalties information subject information requirements exchange act therefore file periodic reports proxy statements information sec reports proxy statements information may obtained visiting public reference room sec f street ne washington dc calling sec sec sending electronic message sec publicinfosecgov sending fax sec addition sec maintains website wwwsecgov contains reports proxy information statements information regarding issuers file electronically table contents mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section make available following filings soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act filings available free charge upon request item risk factors evaluating business carefully consider following risks addition information annual report manifestation following risks could materially adversely affect business results operations financial condition note factors investors permitted private securities litigation reform act possible predict identify factors therefore consider following risks complete statement potential risks uncertainties face substantial portion revenues derived sales hiv products particularly atripla truvada unable maintain continue increasing sales products results operations may adversely affected currently dependent sales products treatment hiv infection particularly atripla truvada support existing operations hiv products contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutics treatment paradigm hiv change causing nucleosidebased therapeutics fall favor unable continue increasing hiv product sales results operations would likely suffer would likely need scale back operations including spending research development rd efforts year ended december atripla truvada product sales together billion total revenues may able sustain growth rate sales hiv products especially atripla truvada number reasons including limited following hiv products used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings contraindications labels narrow approved indications halt sales product could reduce revenues hiv products mature private insurers government reimbursers often reduce amount reimburse patients products increases pressure us reduce prices large part market hiv products consists patients already taking hiv drugs successful encouraging physicians change patients regimens include hiv products sales hiv products limited generic hiv products introduced major markets ability maintain pricing market share may affected fail commercialize new products expand indications existing products prospects future revenues may adversely affected introduce new products market increase sales existing products able increase maintain total revenues continue expand rd efforts drug development inherently risky many product candidates fail drug development process example april announced decision terminate phase b clinical trial gs treatment chronic table contents hepatitis c january announced decision terminate phase clinical trial ambrisentan patients idiopathic pulmonary fibrosis addition january received refuse file notification us food drug administration fda regarding new drug application nda singletablet regimen truvada tibotec pharmaceuticals investigational tmc treatment hiv infection adults fda requested additional information respect chemistry manufacturing controls section nda february refiled new drug application included requested information awaiting fdas response whether substantially complete permit substantive review fda remains unsatisfied completeness application nda may approved timeline obtaining regulatory approval product granted may delayed portion pretax income derived royalty revenue recognized sales tamiflu roche sales tamiflu decrease pretax income disproportionately adversely affected f hoffmannla roche ltd together hoffmannla roche inc roche markets tamiflu worldwide treatment prevention influenza royaltypaying collaborative agreement us recognized million royalty revenue year ended december related royalties received sales tamiflu roche although royalty revenue represented approximately total revenues represented approximately pretax income period roches tamiflu sales unpredictable variability due strong relationship global pandemic planning efforts tamiflu royalties increased sharply first quarter primarily result pandemic planning initiatives worldwide tamiflu royalties declined sharply second quarter due fulfillment many existing pandemic orders governments corporations based roches reported sales tamiflu three months ended december expect tamiflu royalties approximately million first quarter recognize royalties tamiflu sales roche quarter following quarter tamiflu sold sales tamiflu decrease royalty revenues decrease pre tax income decrease disproportionately decrease could material could adversely impact operating results results operations adversely affected current potential future healthcare reforms legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions march healthcare reform legislation adopted united states result required rebate discount products reimbursed paid various public payers including medicaid entities eligible purchase discounted products b drug pricing program public health service act adaps discounts rebates fees legislation impacted us include effective january minimum base rebate amount owed medicaid products reimbursed medicaid increased discounts rebates owe adaps public health service entities reimburse purchase products also increased effective march required extend rebates patients receiving products medicaid managed care organizations effective january required provide discount products sold patients medicare part donut hole effective along pharmaceutical manufacturers branded drug products required pay portion new industry fee also known pharmaceutical excise tax calculated based select government sales calendar year percentage total industry government sales excluding impact new pharmaceutical excise tax estimate impact healthcare reform product sales approximately us net product sales table contents many specific determinations necessary implement healthcare reform legislation yet decided communicated federal government example know many quickly patients receiving product medicare part program reach donut hole details pharmaceutical excise tax calculated reflected financial results based information date estimate impact pharmaceutical excise tax million classified selling general administrative sga expense excise tax tax deductible calculating anticipated financial impacts healthcare reform described made several estimates assumptions respect expected payer mix reforms implemented even though addressed healthcare reform legislation discussions continue federal level legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare part pricing addition state medicaid programs could request additional supplemental rebates products result increase federal base medicaid rebate private insurers could also use enactment increased rebates exert pricing pressure products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services particularly new innovative products therapies resulted lower average selling prices example significant portion sales majority products subject significant discounts list price rebate obligations addition state adaps purchase significant portion hiv products rely federal supplemental federal state funding help fund purchases products federal state funds available amounts sufficient support number patients rely adaps one state currently experiencing sales hiv products could negatively impacted would reduce revenues increased emphasis managed healthcare united states country regional pricing reimbursement controls european union put additional pressure product pricing reimbursement usage may adversely affect product sales profitability pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid healthcare reform pharmaceutical reimbursement policies pricing general europe success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many european countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization months reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates revenuerelated taxes profit control expect prices prescription pharmaceuticals decline life product volumes increase recently many countries european union increased amount discounts required products efforts could continue countries attempt manage healthcare expenditures especially light severe fiscal debt crises experienced many countries european union example table contents june spain imposed incremental discount branded drugs august germany increased rebate prescription pharmaceuticals countries recently imposed could impose similar discounts products generic drugs come market may face price decreases products countries european union approximately product sales occur outside united states currency fluctuations hedging expenses may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates us dollar strengthens foreign currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative value sales increases overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business use foreign currency exchange forward option contracts hedge percentage forecasted international sales primarily denominated euro also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid predict future fluctuations foreign currency exchange rate us dollar us dollar appreciates significantly certain currencies hedging program sufficiently offset effects appreciation results operations adversely affected stock price may decline additionally expenses recognize relation hedging activities also cause earnings fluctuate level hedging expenses recognize particular period impacted changes interest rate spreads foreign currencies hedge us dollar inability accurately estimate demand products well sales fluctuations result inventory levels held wholesalers pharmacies non retail customers make difficult us accurately forecast sales may cause earnings fluctuate could adversely affect financial results stock price approximately product sales united states three wholesalers cardinal health inc mckesson corp amerisourcebergen corp us wholesalers entered inventory management agreements make estimates determine end user demand may completely effective matching inventory levels actual end user demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand addition inventory held retail pharmacies nonwholesale locations inventory management agreements control buying patterns adverse changes economic conditions factors may cause retail pharmacies reduce inventories products would reduce orders wholesalers consequently wholesalers orders us even end user demand changed example second quarter wholesalers increased inventory levels atripla truvada inventory levels viread decreased third quarter wholesalers drew inventory inventory levels atripla truvada end third quarter consistent levels held first quarter inventory distribution channel fluctuates quarter quarter may continue see fluctuations earnings mismatch prescription demand products revenues addition nonretail sector united states includes government institutions including state adaps correctional facilities large health maintenance organizations tends even less consistent table contents terms buying patterns often causes quarter quarter fluctuations necessarily mirror patient demand example first quarter nonretail purchases driven certain state adaps lower percentage federal adap fiscal year purchases compared first quarters believe decrease driven higher purchasing patterns observed last three quarters compared period annual grant cycles federal state adap funds may cause adap purchasing patterns reflect patient demand expect continue experience fluctuations purchasing patterns nonretail customers may result fluctuations product sales revenues earnings future light global economic downturn budget crises faced many europe countries observed variations purchasing patterns induced cost containment measures europe believe measures caused purchasers reduce inventory products distribution channels cases even patient level decreased revenues caused fluctuations product sales earnings may continue see trend future face significant competition face significant competition large pharmaceutical biotechnology companies substantially greater resources addition competitors products operated fields compete longer hiv products compete primarily products joint venture established gsk pfizer markets fixeddose combination products compete atripla truvada example lamivudine marketed joint venture competitive emtricitabine active pharmaceutical ingredient emtriva component atripla truvada may compound patent covering epivir lamivudine expired united states expect see generic lamivudine united states near future generic lamivudine available spain since march expect generic versions lamivudine launched countries within european union early first quarter hepsera viread treatment chronic hepatitis b compete primarily products produced gsk bms novartis pharmaceuticals corporation novartis united states european union china ambisome compete primarily products produced merck pfizer addition aware least two lipid formulations claim similarity ambisome becoming available outside united states including possible entry one formulation greece formulations may reduce market demand ambisome furthermore manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association letairis competes directly product produced actelion pharmaceuticals us inc actelion indirectly pulmonary arterial hypertension products united therapeutics corporation pfizer ranexa competes predominantly generic compounds three distinct classes drugs betablockers calcium channel blockers longacting nitrates treatment chronic angina united states cayston competes product marketed novartis tamiflu competes products sold gsk generic competitors addition number companies pursuing development technologies competitive existing products research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs table contents significant safety issues arise marketed products product candidates future sales may reduced would adversely affect results operations data supporting marketing approvals products forming basis safety warnings product labels obtained controlled clinical trials limited duration cases postapproval use products used longer periods time many patients underlying health problems taking numerous medicines expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings contraindications labels narrow approved indications could reduce market acceptance products product letairis approved fda june member class compounds called endothelin receptor antagonists eras pose specific risks including serious risks liver injury birth defects risks letairis available letairis education access program leap restricted distribution program intended help physicians patients learn risks associated product assure appropriate use product product used additional patients may discover new risks associated letairis may result changes distribution program additional restrictions use letairis may decrease demand product serious safety resistance drug interaction issues arise marketed products sales products could limited halted us regulatory authorities results operations would adversely affected operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda european medicines agency comparable regulatory agencies countries continuing clinical trials atripla truvada viread hepsera emtriva ambisome letairis ranexa cayston currently approved additional uses anticipate file marketing approval additional countries additional indications products next several years products may fail receive marketing approvals timely basis marketed products manufacture sell products subject extensive regulation review discovery previously unknown problems marketed products problems manufacturing promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution example september san dimas manufacturing facility received warning letter fda see risk factor entitled manufacturing problems could delay product shipments regulatory approvals may adversely affect results operations september president bush signed law food drug administration amendments act significantly expanded fdas authority including among things require sponsors marketed products conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk mandate labeling changes products point products lifecycle based new safety information require sponsors implement risk evaluation mitigation strategy product could include medication guide patient package insert communication plan healthcare providers table contents elements fda deems necessary assure safe use drug could include imposing certain restrictions distribution use product failure comply requirements imposed sponsor fda could result significant civil monetary penalties operating results may adversely affected results anticipated timelines clinical trials uncertain may support continued development product pipeline would adversely affect prospects future revenue growth required demonstrate safety efficacy products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products product candidates fails achieve primary endpoint clinical trials safety issues arise results clinical trials otherwise inadequate support regulatory approval product candidates commercialization product candidate could delayed halted example april announced decision terminate phase b clinical trial gs treatment chronic hepatitis c addition may also face challenges clinical trial protocol design clinical trials product candidates pipeline delayed terminated prospects future revenue growth would adversely impacted example face numerous risks uncertainties product candidates including elvitegravir novel hiv integrase inhibitor treatment hiv infection fixeddose regimen elvitegravir cobicistat truvada treatment hiv treatmentnave patients currently phase clinical trials could prevent completion development product candidates risks include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain fda regulatory body approvals result product candidates may never successfully commercialized may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline programs others pipeline completed timely basis prospects future revenue growth may adversely impacted addition clinical trials involving commercial products could raise new safety issues existing products could turn decrease revenues harm business due reliance thirdparty contract research organizations conduct clinical trials unable directly control timing conduct expense quality clinical trials extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent third party contract research organizations cros perform clinical studies including document preparation site identification screening preparation prestudy visits training program management bioanalytical analysis many important aspects services performed us cros direct control dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros processes methodologies results determined invalid inadequate clinical data results related regulatory approvals could adversely impacted depend relationships companies sales marketing performance revenues failure maintain relationships poor performance companies disputes companies could negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance certain territories include collaborations bms atripla united states europe canada roche tamiflu worldwide gsk ambrisentan territories outside table contents united states countries rely international distributors sales truvada viread hepsera emtriva ambisome relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk unable control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us particularly light current economic conditions given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major markets hepsera china japan taiwan south korea november entered agreement gsk provided gsk exclusive commercialization rights registration responsibilities viread treatment chronic hepatitis b china october granted similar rights gsk japan saudi arabia success hepsera viread treatment chronic hepatitis b territories depends almost entirely efforts gsk regard gsk promotes epivirhbvzeffix product competes hepsera viread treatment chronic hepatitis b consequently gsks marketing strategy hepsera viread treatment chronic hepatitis b may influenced promotion epivirhbvzeffix receive royalties gsk equal percentage gsks net sales hepsera viread treatment chronic hepatitis b well net sales gsks epivirhbvzeffix gsk fails devote sufficient resources succeed developing commercializing hepsera viread treatment chronic hepatitis b territories potential revenues territories may substantially reduced addition cayston letairis distributed thirdparty specialty pharmacies pharmacies specializing dispensing medications complex chronic conditions may require high level patient education ongoing counseling use specialty pharmacies requires significant coordination sales marketing medical affairs regulatory affairs legal finance organizations involves risks including limited risks specialty pharmacies provide us accurate timely information regarding inventories patient data safety complaints effectively sell support cayston letairis devote resources necessary sell cayston letairis volumes within time frames expect table contents able satisfy financial obligations us others cease operations also rely third party administer leap restricted distribution program designed support letairis third party provides information education prescribers patients risks letairis confirms insurance coverage investigates alternative sources reimbursement assistance ensures fulfillment risk management requirements mandated letairis fda coordinates controls dispensing patients third party specialty pharmacies failure third party specialty pharmacies distribute letairis perform expected may result regulatory action fda decreased letairis sales either would harm business cayston may taken patients using specific inhalation device delivers drug lungs patients ongoing distribution cayston entirely reliant upon manufacturer device example manufacturer could encounter issues regulatory agencies related device unable supply sufficient quantities device addition manufacturer may able provide adequate warranty support device distributed patients respect distribution drug device patients reliant capabilities specialty pharmacies example distribution channel drug device complicated requires coordination reimbursement approval processes associated drug device similarly complex device manufacturer unable obtain reimbursement approval receives approval lowerthanexpected price sales cayston may adversely affected previously described issues may limit sales cayston would adversely affect financial results expenses associated clinical trials may cause earnings fluctuate could adversely affect stock price clinical trials required regulatory approval products well clinical trials required conduct approval expensive difficult accurately predict control amount timing expenses quarter quarter fda andor regulatory agencies may require clinical testing originally anticipated uneven unexpected spending programs may cause operating results fluctuate quarter quarter stock price may decline success depend significant degree ability protect patents intellectual property rights domestically internationally may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology patents proprietary rights important business success depend significant degree ability obtain patents licenses patent rights preserve trade secrets operate without infringing proprietary rights others properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide table contents adequate protection pending patent applications result issued patents patent applications confidential period time patent issued result may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings unpredictable expensive even ultimately successful results operations may adversely affected events time time certain individuals entities may challenge patents example public patent foundation filed requests reexamination united states patent trademark office pto challenging four patents related tenofovir disoproxil fumarate active ingredient atripla truvada viread pto granted requests issued nonfinal rejections four patents step common proceeding initiate reexamination process pto confirmed patentability four patents although successful responding pto actions instance similar organizations may still challenge patents foreign jurisdictions example april brazilian health ministry citing us patent reexamination proceedings grounds rejection requested brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issued final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate filed brazil filed appeal within patent authority responding questions raised rejection july brazilian patent authority rejected application highest level appeal available us within brazilian patent authority filed civil action brazilian federal court appeal action brazilian patent authority predict outcome proceeding tenofovir disoproxil fumarate patent application unsuccessful appeal courts decision patent authority brazilian government would likely purchase generic tenofovir disoproxil fumarate would significantly reduce sales hiv products brazil brazilian government purchased approximately million hiv products aware applications two generic companies sell generic version viread brazil one generic applicants able compete contract would expect brazilian government purchase hiv products another example patent office india initially allowed claims covering tenofovir disoproxil tenofovir disoproxil fumarate however indian civil procedure prior official grant allowed applications several parties filed legal actions protest decision grant patents august indian patent office announced decided actions us would therefore allow patents granted filed appeal within indian patent office intellectual property appellate board applications predict outcome proceedings unsuccessful appeal decisions appeals pursued indian court system may ultimately prove unsuccessful meantime competitor able sell generic tenofovir disoproxil fumarate india addition unsuccessful appealing negative decisions indian patent office indian courts competitors would able continue sell generic tenofovir disoproxil fumarate could reduce amount royalties receive indian generic licenses patents cover ranolazine active ingredient ranexa instead discovered sustained release formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve patents cover active ingredients ambisome addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hepatitis b indication hepsera developed table contents may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions countries part approval process products fda granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products generic manufacturers sought may continue seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug example november received notice teva pharmaceuticals teva submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic version atripla notice teva challenged two emtricitabine patents may filed another lawsuit teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir disoproxil fumarate patents protecting viread january also received notices teva amending andas related atripla truvada notice related truvada teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine notice related atripla teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine two patents related efavirenz march filed lawsuit teva infringement four viread patents two additional emtricitabine patents march bms merck filed lawsuit teva infringement patents related efavirenz june received notice lupin limited lupin submitted anda fda requesting permission manufacture market generic version ranexa notice lupin alleges ten patents associated ranexa invalid unenforceable andor infringed lupins manufacture use sale generic version ranexa july filed lawsuit lupin infringement patents ranexa august received notice sigmapharm labs sigmapharm submitted anda fda requesting permission manufacture market generic version hepsera notice sigmapharm alleges patents associated hepsera invalid unenforceable andor infringed sigmapharms manufacture use sale generic version hepsera september filed lawsuit sigmapharm infringement patents hepsera one patents challenged sigmapharm also challenged ranbaxy inc ranbaxy pursuant notice received october patent challenged ranbaxy expires july option filing lawsuit time believe ranbaxy infringing patent february received notice natco pharma limited natco submitted anda fda requesting permission manufacture market generic version tamiflu notice natco alleges patent associated tamiflu invalid unenforceable andor infringed natcos manufacture use sale generic version tamiflu currently reviewing notice letter days date receipt commence patent infringement lawsuit natco table contents predict ultimate outcome actions may spend significant resources enforcing patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states could substantially shortened patents covering products invalidated fda could approve requests manufacture generic version products prior expiration date patents success depends large part ability operate without infringing upon patents proprietary rights third parties infringe patents others may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware body patents may relate operation leap restricted distribution program designed support letairis furthermore use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors manufacturing problems could delay product shipments regulatory approvals may adversely affect results operations depend third parties perform manufacturing activities effectively timely basis majority solid dose products addition roche either third parties responsible manufacturing tamiflu manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations thirdparty manufacturers corporate partners subject current good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda european medicines agency similar regulations effect countries thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected manufacturing operations subject routine inspections regulatory agencies example january february fda conducted routine inspection san dimas california manufacturing distribution facility manufacture ambisome cayston fill finish macugen package solid dosage form products conclusion inspection fda issued form inspectional observations stating concerns maintenance aseptic processing conditions manufacturing suite ambisome product environmental maintenance issues san dimas warehousing facility batch sampling timeliness completion annual product quality reports september san dimas manufacturing facility received warning letter fda detailing fdas concerns ambisome manufacturing environment including control systems monitoring procedures prevent microbiological contamination preventative cleaning equipment maintenance referencing certain viread lots letter also stated concerns connected quality procedures controls investigation procedures generalized concern effectiveness san dimas quality unit carrying responsibilities table contents november december fda reinspected san dimas facility reinspection closed additional form observations consequently believe addressed fdas concerns stated form observations warning letter awaiting confirmation acceptance fda unless receive confirmation fda satisfied corrected outstanding issues fda may withhold permission export ambisome cayston manufactured san dimas certain countries outside united states europe fda may also withhold approval pending drug applications listing san dimas facility since required notified appropriate international regulatory authorities letters issuance possible letter may impact ability supply aseptic products manufactured san dimas ambisome cayston macugen outside united states result warning letter unable receive export regulatory approvals ambisome products issue may unable sell sufficient quantities products meet market demand would decrease revenues harm business described risk factor entitled may able obtain materials supplies necessary conduct clinical trials manufacture sell products would limit ability generate revenues manufacture ambisome fill finish macugen exclusively san dimas facility believe warning letter impact ability supply solid dosage form products package san dimas facility include atripla truvada viread emtriva hepsera letairis ranexa event solid dosage form products affected alternate sites could supply products ability successfully manufacture commercialize cayston depend upon ability manufacture multiproduct facility aztreonam active pharmaceutical ingredient cayston monobactam gramnegative antibiotic manufacture cayston san dimas california third parties multiproduct manufacturing facilities historically fda permitted manufacture monobactams multiproduct manufacturing facilities however assurance fda continue allow practice currently singleproduct facility dedicated manufacture cayston engaged contract manufacturer singleproduct facility cayston fda prohibits manufacture monobactam antibiotics like aztreonam multiproduct manufacturing facilities future may able procure singleproduct manufacturing facility timely manner would adversely affect commercial supplies cayston anticipated financial results attributable product september san dimas manufacturing facility received warning letter fda see risk factor entitled manufacturing problems could delay product shipments regulatory approvals may adversely affect results operations possible warning letter may impact ability supply cayston manufactured san dimas outside united states would decrease revenues harm business may able obtain materials supplies necessary conduct clinical trials manufacture sell products would limit ability generate revenues need access certain supplies products conduct clinical trials manufacture products light global economic downturn increased difficulty purchasing certain raw materials used manufacturing process unable purchase sufficient quantities materials find suitable alternate materials timely manner development efforts product candidates may delayed ability manufacture products would limited would limit ability generate revenues table contents suppliers key components materials must named nda filed fda product candidate seeking fda approval significant delays occur qualification new supplier required even manufacturer qualified fda manufacturer must continue expend time money effort area production quality control ensure full compliance gmp manufacturers subject regular periodic inspections fda following initial approval result inspections fda determines equipment facilities laboratories processes comply applicable fda regulations conditions product approval fda may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand would turn decrease revenues harm business addition delivery material suppliers interrupted reason may unable ship certain products commercial supply supply products development clinical trials addition products materials utilize operations made one facility example manufacture ambisome fill finish macugen exclusively facilities san dimas california event disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome macugen meet market needs cayston dependent two different thirdparty singlesource suppliers first aztreonam active pharmaceutical ingredient aztreonam inhalation solution manufactured single supplier single site second administered lungs patients device made single supplier single site disruptions delays single suppliers could adversely affect ability supply cayston sure alternative suppliers identified timely manner see risk factor entitled ability successfully manufacture commercialize cayston depend upon ability manufacture multiproduct facility addition depend single supplier high quality cholesterol used manufacture ambisome also depend single suppliers active pharmaceutical ingredient vistide ranexa cayston tableting emtriva letairis astellas us llc markets lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan problems single suppliers depend may negatively impact development commercialization efforts significant portion raw materials intermediates used manufacture hiv products atripla truvada viread emtriva supplied chinesebased companies result international trade dispute china united states actions chinese government would limit prevent chinese companies supplying materials would adversely affect ability manufacture supply hiv products meet market needs material adverse effect operating results face credit risks european customers may adversely affect results operations european product sales governmentowned supported customers greece italy portugal spain subject significant payment delays due government funding reimbursement practices resulted may continue result increase days sales outstanding due average length time accounts receivable outstanding accounts receivable countries totaled approximately million december million days past due based contractual payment terms result fiscal debt crises countries number days invoices past due continued increase line experienced pharmaceutical companies also selling directly hospitals historically receivables balances certain publiclyowned hospitals accumulate period time subsequently settled large lump sum payments significant changes occur reimbursement practices european governments table contents government funding becomes unavailable may able collect amounts due us customers results operations would adversely affected example december million due publiclyowned hospitals greece greek government offered settle majority outstanding receivables zerocoupon bonds expected trade discount face value agreed accept bonds december received bonds settle receivables totaling million anticipate receiving remaining bonds full end first quarter december allowance doubtful accounts adequate cover exposure related expected discount bonds spain italy portugal actively pursuing collection overdue receivables taking action necessary enforce legal right payment revenues gross margin could reduced imports countries products available lower prices prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly truvada viread agreed make available substantially reduced prices countries participating gilead access program atripla merck distributes substantially reduced prices hiv infected patients developing countries august agreement revenues would adversely affected addition established partnerships thirteen indian generic manufacturers distribute highquality lowcost generic versions tenofovir disoproxil fumarate developing world countries including india generic versions medications licenses reexported united states europe markets outside countries revenues would adversely affected addition purchases products countries selling prices relatively low resale countries selling prices relatively high may adversely impact revenues gross margin may cause sales fluctuate quarter quarter example european union required permit products purchased one country sold another country purchases products countries selling prices relatively low resale countries selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter reflect actual consumer demand given quarter quarterly fluctuations may impact earnings could adversely affect stock price harm business expensive litigation government investigations may reduce earnings november received notice teva submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic version atripla notice teva challenged two emtricitabine patents may filed another lawsuit teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir disoproxil fumarate patents protecting viread january also received notices teva amending andas related atripla truvada notice related truvada teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine notice related atripla teva challenged four table contents patents related tenofovir disoproxil fumarate two additional patents related emtricitabine two patents related efavirenz march filed lawsuit teva infringement four viread patents two additional emtricitabine patents march bms merck filed lawsuit teva infringement patents related efavirenz june received notice lupin submitted anda fda requesting permission manufacture market generic version ranexa notice lupin alleges ten patents associated ranexa invalid unenforceable andor infringed lupins manufacture use sale generic version ranexa july filed lawsuit lupin infringement patents ranexa august received notice sigmapharm submitted anda fda requesting permission manufacture market generic version hepsera notice sigmapharm alleges patens associated hepsera invalid unenforceable andor infringed sigmapharms manufacture use sale generic version hepsera september filed lawsuit sigmapharm infringement patents hepsera one patents challenged sigmapharm also challenged ranbaxy pursuant notice received october patent challenged ranbaxy expires july considering options enforcing patent february received notice natco submitted anda fda requesting permission manufacture market generic version tamiflu notice natco alleges patent associated tamiflu invalid unenforceable andor infringed natcos manufacture use sale generic version tamiflu currently reviewing notice letter days date receipt commence patent infringement lawsuit natco predict ultimate outcome actions may spend significant resources enforcing patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states could substantially shortened patents covering products invalidated fda could approve requests manufacture generic version products prior expiration date patents outcome lawsuits lawsuits may brought us inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us could significantly reduce earnings cash flows harm business countries may required grant compulsory licenses products face generic competition products number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread july brazilian patent authority rejected patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread highest level appeal available us within brazilian patent authority filed civil action brazilian federal court appeal action brazilian patent authority unable successfully appeal decision patent authority courts brazilian government would likely purchase generic tenofovir disoproxil fumarate would significantly reduce sales hiv products table contents brazil brazilian government purchased approximately million hiv products aware applications two generic companies sell generic version viread brazil one generic applicants able compete contract would expect brazilian government purchase hiv products addition concerns cost availability tamiflu related potential avian flu pandemic hn influenza generated international discussions compulsory licensing tamiflu patents example canadian government may allow canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canadas access medicines regime furthermore roche issued voluntary licenses permit thirdparty manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit thirdparty manufacturing tamiflu developments could reduce royalties receive roches sales tamiflu certain countries permit enforcement patents thirdparty manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales may face significant liability resulting products may covered insurance successful claims could materially reduce earnings testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others recent years coverage availability costeffective product liability insurance decreased may unable maintain sufficient coverage product liabilities may arise addition cost defend lawsuits pay damages product liability claims may exceed coverage unable maintain adequate coverage claims exceed coverage financial condition ability clinically test product candidates market products adversely impacted addition negative publicity associated claims regardless merit may decrease future demand products impair financial condition business disruptions natural manmade disasters may harm future revenues worldwide operations could subject business interruptions stemming natural manmade disasters may selfinsured corporate headquarters palo alto locations together house majority research development activities san dimas manufacturing facility located california seismically active region carry earthquake insurance significant recovery time could required resume operations financial condition operating results could materially adversely affected event major earthquake changes effective income tax rate could reduce earnings various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates portion nontax deductible pharmaceutical excise tax required pay starting result enactment us healthcare reform legislation accounting stock options sharebased payments mergers acquisitions future levels rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact net income table contents income tax returns audited federal state foreign tax authorities currently examination internal revenue service tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions resolution one exposures reporting period could material impact results operations period changes accounting rules policies may affect financial position results operations us generally accepted accounting principles related implementation guidelines interpretations highly complex involve subjective judgments changes rules interpretation adoption new guidance application existing guidance changes business could significantly affect financial position results operations fail attract retain highly qualified personnel may unable successfully develop new product candidates conduct clinical trials commercialize product candidates future success depend large part continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization face competition personnel companies universities public private research institutions government entities organizations competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit may able attract retain quality personnel acceptable terms unsuccessful recruitment retention efforts business may harmed item b unresolved staff comments applicable item properties corporate headquarters including principal offices commercial administrative research development rd facilities located foster city california buildings lease facilities foster city palo alto san dimas california house manufacturing warehousing rd activities addition also lease facilities branford connecticut seattle washington house administrative rd activities international headquarters include commercial medical administrative facilities located leased london area united kingdom manufacturing facility cork ireland primarily use solid dose tablet manufacturing antiviral products well product packaging activities also lease facilities dublin area ireland house distribution activities also manufacturing facility edmonton alberta canada primarily use conduct process research scaleup clinical development candidates manufacturing active pharmaceutical ingredients investigational commercial products chemical development activities improve existing commercial manufacturing processes leased additional facilities house commercial medical administrative activities australia austria belgium canada france germany greece ireland italy netherlands poland portugal table contents spain sweden switzerland turkey united kingdom also lease office shanghai china provide sourcing manufacturing support primarily related commercial purchases active pharmaceutical ingredients believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings november received notice teva submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine owned emory university licensed exclusively us invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit us district court new york teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic version atripla notice teva challenged two emtricitabine patents may filed another lawsuit us district court new york teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir disoproxil fumarate patents protecting viread january also received notices teva amending andas related atripla truvada notice related truvada teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine notice related atripla teva challenged four patents related tenofovir disoproxil fumarate two additional patents related emtricitabine two patents related efavirenz march filed lawsuit teva infringement four viread patents two additional emtricitabine patents march bms merck filed lawsuit teva infringement patents related efavirenz june received notice lupin submitted anda fda requesting permission manufacture market generic version ranexa notice lupin alleges ten patents associated ranexa invalid unenforceable andor infringed lupins manufacture use sale generic version ranexa july filed lawsuit us district court new jersey lupin infringement patents ranexa august received notice sigmapharm submitted anda fda requesting permission manufacture market generic version hepsera notice sigmapharm alleges patents associated hepsera invalid unenforceable andor infringed sigmapharms manufacture use sale generic version hepsera september filed lawsuit us district court new jersey sigmapharm infringement patents hepsera one patents challenged sigmapharm also challenged ranbaxy inc ranbaxy pursuant notice received october patent challenged ranbaxy expires july considering options enforcing patent february received notice natco submitted anda fda requesting permission manufacture market generic version tamiflu notice natco alleges patent associated tamiflu invalid unenforceable andor infringed natcos manufacture use sale generic version tamiflu currently reviewing notice letter days date receipt commence patent infringement lawsuit natco predict ultimate outcome actions may spend significant resources enforcing patents unsuccessful lawsuits original claims patents may table contents narrowed invalidated patent protection atripla truvada viread hepsera ranexa tamiflu united states could substantially shortened patents covering products invalidated fda could approve requests manufacture generic version products prior expiration date patents information pertaining certain legal proceedings found item note consolidated financial statements included annual report item reserved table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild following table sets forth high low intraday sale prices per share common stock nasdaq global select market periods indicated prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception currently expect retain earnings primarily use operation expansion business therefore anticipate paying cash dividends near future effort continue return value stockholders minimize dilution stock issuances board directors board authorized program january repurchase common stock amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means completed plan may time board authorized threeyear billion stock repurchase program december repurchased billion common stock program utilized total billion repurchase retire million shares common stock average purchase price per share january board authorized additional threeyear billion stock repurchase program commence upon completion existing program authorized may intend use additional authorization repurchase shares time time offset dilution created shares issued employee stock plans repurchase shares opportunistically see item note consolidated financial statements included annual report information regarding stock repurchase programs performance graph following graph compares total stockholder returns past five years two indices standard poors stock index labeled sp index nasdaq biotechnology index labeled nbi index total return index assumes reinvestment dividends paid companies included indices calculated december year composite member sp index nbi index intend use indices comparators stock performance purposes following graph going forward table contents composite member sp index required applicable regulations use index comparator believe nbi index relevant comparator since composed peer companies linesofbusiness similar stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed sec incorporated reference filings securities act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december issuer purchases equity securities effort continue return value stockholders minimize dilution stock issuances board authorized program january repurchase common stock amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means completed plan may time board authorized threeyear billion stock repurchase program december repurchased billion common stock program utilized total billion repurchase retire million shares common stock average purchase price per share table contents january board authorized additional threeyear billion stock repurchase program commence upon completion existing program authorized may intend use additional authorization repurchase shares time time offset dilution created shares issued employee stock plans repurchase shares opportunistically see item note consolidated financial statements included annual report information regarding stock repurchase programs table summarizes stock repurchase activity three months ended december thousands except per share amounts total number maximum fair value shares purchased shares may yet total number average price paid part publicly purchased shares purchased per share announced programs program october october november november december december total difference total number shares purchased total number shares purchased part publicly announced programs due shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations table contents item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement income data total revenues total costs expenses income loss operations provision income taxes net income loss attributable gilead net income loss per share attributable gilead common stockholdersbasic shares used per share calculationbasic net income loss per share attributable gilead common stockholdersdiluted shares used per share calculationdiluted december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible senior notes retained earnings accumulated deficit total stockholders equity recorded million impairment charges rd expense related certain inprocess research development iprd assets acquired cv therapeutics inc cv therapeutics see item notes consolidated financial statements included annual report completed acquisition assets navitas assets llc related cicletanine business aggregate purchase price million allocated purchased iprd completed acquisition myogen inc aggregate purchase price billion billion allocated purchased iprd also acquired net assets corus pharma inc million million allocated purchased iprd completed acquisition cv therapeutics recognized consideration transferred billion primarily recorded intangible assets see item note consolidated financial statements included annual report issued billion principal amount convertible senior notes private placement see item note consolidated financial statements included annual report issued billion principal amount convertible senior notes private placement see item note consolidated financial statements included annual report table contents item managements discussion analysis financial condition results operations following managements discussion analysis financial condition results operations mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes consolidated financial statements disclosures included annual report including disclosures item risk factors consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars management overview biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need mission advance care patients suffering life threatening diseases worldwide headquartered foster city california operations north america europe asia pacific market products hivaids liver disease respiratory cardiovascularmetabolic therapeutic areas product portfolio comprised atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg truvada emtricitabine tenofovir disoproxil fumarate viread tenofovir disoproxil fumarate emtriva emtricitabine treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil viread treatment chronic hepatitis b ambisome amphotericin b liposome injection treatment severe fungal infections letairis ambrisentan treatment pulmonary arterial hypertension pah ranexa ranolazine treatment chronic angina vistide cidofovir injection treatment cytomegalovirus infection cayston aztreonam inhalation solution treatment improve respiratory symptoms cystic fibrosis cf patients pseudomonas aeruginosa p aeruginosa addition also sell distribute certain products corporate partners royaltypaying collaborative agreements example f hoffmannla roche ltd together hoffmannla roche inc roche markets tamiflu oseltamivir phosphate treatment prevention influenza glaxosmithkline inc gsk markets hepsera viread treatment chronic hepatitis b certain territories outside united states gsk also markets volibris ambrisentan outside united states treatment pah astellas pharma us inc markets ambisome treatment severe fungal infections united states canada astellas us llc markets lexiscan regadenoson injection united states use pharmacologic stress agent radionuclide myocardial perfusion imaging rapidscan pharma solutions inc markets rapiscan regadenoson certain territories outside united states inducement pharmacological stress andor vasodilation coronary vasculature strictly purposes diagnosing cardiovascular disease menarini international operations luxembourg sa markets ranexa certain territories outside united states treatment chronic angina japan tobacco inc japan tobacco markets truvada viread emtriva japan business highlights grew business significantly achieved record total revenues billion strengthening product portfolio pipeline programs antiviral franchise particular atripla truvada continued drive product sales growth united states within big five european union markets comprised united kingdom france germany italy spain cardiovascular franchise also delivered strong results year contributions letairis ranexa total revenues newest product cayston respiratory area well accepted north america certain countries europe showing continued revenue growth throughout table contents year also made strategic decisions advance focus research development rd pipeline efforts including hiv area september announced submitted marketing authorization application european medicines agency marketing approval singletablet regimen truvada tibotec pharmaceuticals tibotec investigational nonnucleoside reverse transcriptase inhibitor tmc rilpivirine hydrochloride treatment hiv infection adults november announced submitted new drug application nda us food drug administration fda marketing approval singletablet regimen truvada tibotecs tmc treatment hiv infection adults january received refuse file notification us fda communication fda requested additional information respect chemistry manufacturing controls section nda submission february refiled new drug application included requested information awaiting fdas response whether substantially complete permit substantive review also hiv area initiated phase clinical studies investigational fixeddose singletablet quad regimen elvitegravir cobicistat formerly gs truvada two phase studies evaluating singletablet fixeddose regimen versus standard care among hivinfected treatmentnave patients second quarter also initiated phase study evaluating efficacy safety tolerability cobicistat pharmacoenhancer development boosting agent certain hiv medicines antivirals september released positive week results two ongoing phase clinical studies hivinfected patients first study fixeddose singletablet quad regimen elvitegravir cobicistat truvada versus atripla second study cobicistatboosted atazanavir plus truvada compared ritonavirboosted atazanavir plus truvada liver disease area hepatitis c virus hcv pipeline includes seven unique molecules spanning six therapeutic classes different mechanisms action five compounds currently clinical trials two slated enter human clinical studies early october announced data phase study showing investigational compounds gs gs used conjunction current standard care therapies produced substantial suppression hcv within days treatment additionally october announced new data openlabel phase two pivotal phase clinical trials studies evaluating fouryear efficacy viread treatment chronic hepatitis b virus hbv infection show viread maintains antiviral suppression development resistance four years treatment data also show significant antigen loss marker resolution chronic hbv infection hbeagpositive patients also liver disease area july john mchutchison md joined gilead senior vice president liver disease therapeutics lead efforts advance discovery development programs liver disease area respiratory area announced october headtohead phase clinical trial cayston versus tobramycin inhalation solution tis cf patients p aeruginosa achieved coprimary endpoint superiority cayston tis mean actual change forced expiratory volume one second fev measure lung function percent predicted across three treatment cycles six months earlier year february received marketing approval fda cayston treatment improve respiratory symptoms cf patients p aeruginosa cardiovascular metabolic areas december announced termination artemisipf phase study ambrisentan patients idiopathic pulmonary fibrosis ipf decision follows interim analysis unblinded efficacy safety data studys data monitoring committee review data show evidence treatment benefit group patients randomized receive ambrisentan table contents year also expanded pipeline strategic acquisitions completed acquisition arresto biosciences inc arresto january million plus potential future payments based achievement certain sales levels arresto privatelyheld developmentstage biotechnology company based palo alto california focused developing antibodies potential treatment fibrotic diseases cancer companys lead product gs formerly ab humanized monoclonal antibody mab targeting human lysyl oxidaselike loxl protein addition ongoing phase study gs patients advanced solid tumors phase study conducted evaluate gs patients ipf completed acquisition cgi pharmaceuticals inc cgi july million cash majority upfront payment remaining based achievement certain clinical development milestones cgi privatelyheld development stage pharmaceutical company based branford connecticut primarily focused small molecule chemistry protein kinase biology lead preclinical compound cgis library proprietary small molecule kinase inhibitors targets spleen tyrosine kinase syk could unique applications treatment serious inflammatory diseases including rheumatoid arthritis financial highlights operating results led total product sales billion increase total product sales billion increase product sales driven primarily antiviral franchise atripla truvada viread hepsera emtriva due mainly strong growth atripla sales atripla contributed billion antiviral product sales atripla product sales increased primarily due sales volume growth united states europe truvada product sales comprised billion antiviral product sales truvada product sales increased primarily due sales volume growth united states europe foreign currency exchange unfavorable impact million million revenues pretax earnings respectively compared product sales united states driven primarily antiviral franchise also reflected growth sales cardiovascular products antiviral product sales united states increased compared resulting continued growth patient market share united states respect cardiovascular franchise ranexa sales united states million reflecting continued growth demand ranexa prescriptions increased since acquisition cv therapeutics inc cv therapeutics april ranexa sales million period subsequent acquisition cv therapeutics furthermore letairis sales contributed million product sales united states reflecting increase newest product cayston also contributed million first year sales majority united states product sales europe driven antiviral product sales increased compared due continued strong growth demand saw demand growth products europe effect partially offset recent mandatory price reductions certain european countries foreign currency exchange impact strengthening us dollar relative european currencies royalty revenues recognized collaborations corporate partners million increase million royalty revenues million royalty revenues include royalties gsk hepsera royalties astellas lexiscan royalties japan tobacco truvada contributed increase total royalty revenues partially offset tamiflu royalties roche decreased million million rd selling general administrative sga expenses increased million compared increase due primarily impairment charges related inprocess rd table contents iprd assets acquired cv therapeutics higher headcount expenses support expanding commercial activities clinical studies expenses related increased hiv research activities partially offset lower rd expense reimbursement related collaboration tibotec approved communicated plan second quarter close research operations durham north carolina consolidate liver disease research activities foster city california believe plan allow employees collaborate effectively advance programs liver disease area year incurred total million restructuring expenses related employee severance facilitiesrelated expenses plan december closed operations durham expect incur additional significant costs connection plan financing activity cash cash equivalents marketable securities increased billion driven primarily operating cash flows billion proceeds billion issuance convertible senior notes net issuance costs partially offset repurchases common stock stock repurchase programs current threeyear billion stock repurchase program authorized may repurchased billion common stock december may completed billion stock repurchase program previously authorized january year utilized total billion cash repurchase retire million shares common stock average purchase price per share board authorized additional threeyear billion stock repurchase program january future repurchases outstanding shares common stock commence upon completion existing program authorized may intend use additional authorization repurchase shares time time offset dilution created shares issued employee stock plans repurchase shares opportunistically issued billion convertible senior notes july private placement purchased convertible note hedges well sold warrants net cost million cost convertible note hedges tax deductible life notes convertible note hedges warrants intended reduce potential economic dilution upon future conversions notes effectively increasing conversion prices notes interest expense increased million compared due primarily increased interest expense related notes used continue use net proceeds issuance convertible notes repurchase shares common stock repay existing indebtedness healthcare reform march healthcare reform legislation adopted united states result required rebate discount products reimbursed paid various public payers including medicaid entities eligible purchase discounted products b drug pricing program public health service act aids drug assistance programs adaps discounts rebates fees legislation impacted us include effective january minimum base rebate amount owed medicaid products reimbursed medicaid increased discounts rebates owe adaps public health service entities reimburse purchase products also increased effective march required extend rebates patients receiving products medicaid managed care organizations effective january required provide discount products sold patients medicare part donut hole table contents effective along pharmaceutical manufacturers branded drug products required pay portion new industry fee also known pharmaceutical excise tax calculated based select government sales calendar year percentage total industry government sales starting number people access healthcare coverage expected increase could experience positive impact sales products expansion healthcare coverage may decrease reliance patients state adaps currently rely availability federal state funding full impact healthcare reform reduction approximately million us net product sales majority impact began third quarter continued throughout fourth quarter since new discount rebate requirements took two quarters fully take effect excluding impact new pharmaceutical excise tax estimate impact healthcare reform product sales approximately us net product sales many specific determinations necessary implement healthcare reform legislation yet decided communicated federal government example know many quickly patients receiving product medicare part program reach donut hole details pharmaceutical excise tax calculated based information date estimate impact pharmaceutical excise tax million classified sga expense excise tax tax deductible calculating anticipated financial impacts healthcare reform described made several estimates assumptions respect expected payer mix reforms implemented outlook operating objectives include increasing market share commercial products continuing strengthen pipeline internally developed andor externally inlicensed purchased opportunities strengthening key alliances additionally remain committed returning value shareholders continue repurchase shares disciplined manner throughout year rd standpoint continue execute pipeline development particular focus innovative hiv singletablet regimens patients progression hcv molecules clinic commercial standpoint number internal external initiatives intended promote continued growth franchises hiv area expect see continued positive impact revised us department health human services treatment guidelines recommend earlier treatment patients hiv extension ryan white treatment act provide stable funding adaps united states assuming timely resolution issues refuse file notification fda expect launch singletablet regimen truvada tibotecs tmc second half expect contribute incremental revenue hiv franchise february refiled new drug application included requested information awaiting fdas response whether substantially complete permit substantive review hepatitis b virus hbv area continue support educational promotional activities focused us asian communities highlighting need screen diagnose link patients care part efforts expanded hepatitis b field team united states cardiovascular area continue efforts raise awareness gilead pah cardiology communities believe help grow revenues letairis ranexa cystic fibrosis intend expand field team grow market share cayston mindful conditions current macroeconomic environment could affect ability achieve goals factors could affect business include future changes healthcare table contents reform united states continuation worsening global economic conditions patent expirations competitive products launch generic competitors continued government pricing pressures internationally potential volatility foreign currency exchange rates continue monitor conditions adjust business processes appropriate mitigate risks business successes experienced helped us maintain build financially sound business model believe allow us continue expand commercial collaborative rd activities maintain quality compliance continue grow business remain focused profitable revenue growth prudent expense management believe enable solid execution operating objectives critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate estimates including related revenue recognition intangible assets allowance doubtful accounts prepaid royalties clinical trial accruals tax provision stockbased compensation base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognition product sales recognize revenues product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectability reasonably assured record estimated reductions revenues government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products estimates deducted gross product sales time revenues recognized reductions gross product sales government rebates significantly impact reported net product sales based upon certain estimates require complex significant judgment management government rebates estimate reductions revenues governmentmanaged medicaid programs well certain qualifying federal state foreign government programs reimbursement portions retail price prescriptions filled covered programs reductions settled either company invoiced directly chargebacks wholesalers government rebates invoiced directly us recorded accrued government rebates consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower contractual government price record allowances accounts receivable although may pay rebates countries outside united states date payments made foreign governments represented significant portion total government rebates government programs united states estimate sales allowances based contractual terms historical utilization rates new information regarding changes programs regulations guidelines would impact amount actual rebates table contents expectations regarding future utilization rates programs channel inventory data obtained major us wholesalers accordance inventory management agreements us government rebates billion million million respectively representing total gross product sales respectively deducted gross product sales believe methodology use estimate sales allowances government price reductions reasonable appropriate given current facts circumstances however actual results may differ based current information available us actual government rebates claimed periods varied less estimates recorded periods december accrued us government rebates million million respectively accrued government rebates allowance doubtful accounts million million respectively recorded accounts receivable following table summarizes aggregate activity us government rebates allowance accrued liabilities accounts balance deducted balance beginning charged end year expense accruals year year ended december government rebates allowances accrued liabilities activity related sales activity related sales prior total year ended december government rebates allowances accrued liabilities activity related sales activity related sales prior total intangible assets conjunction business combinations completed recorded intangible assets primarily related marketed products iprd projects goodwill part recognition measurement assets acquired liabilities assumed business combination identifiable intangible assets related marketed products iprd projects measured respective fair values acquisition date believe fair values assigned acquired intangible assets based reasonable estimates assumptions given available facts circumstances acquisition dates discounted cash flow models used valuing intangible assets models require use significant estimates assumptions including limited estimates revenues operating profits related products product candidates probability success unapproved product candidates considering stages development time resources needed complete development approval product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets goodwill represents excess consideration transferred estimated fair values assets acquired liabilities assumed business combination goodwill intangible assets determined indefinite useful lives amortized required tested impairment least annually test table contents goodwill indefinitelived intangible assets impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair values assets carrying amounts december million indefinitelived intangible assets consisting million goodwill resulting various business combinations million intangible assets related iprd projects acquired cgi cv therapeutics intangible assets finite useful lives amortized estimated useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable amortizing intangible asset related ranexa product acquired cv therapeutics estimated useful life using amortization rate derived forecasted future product sales ranexa product sales forecasts prepared annually determined using best estimates future activity upon considering factors historical expected future patient usage uptake products introduction complimentary combination therapies products future product launch plans previously unanticipated significant change occurs sales forecasts prospectively update rate used amortize intangible asset related ranexa may increase future cost goods sold record amortization expense amortizing intangible asset related lexiscan product also acquired cv therapeutics estimated useful life cost goods sold straightline basis given current lexiscan revenues consist royalties received collaboration partner lack ongoing access visibility partners future sales forecasts make reasonable estimate amortization rate using forecasted product sales approach december million net unamortized finitelived intangible assets consisting primarily intangible assets related marketed products acquired cv therapeutics judgment regarding existence impairment indicators based historical projected future operating results extent manner use acquired assets legal regulatory factors events overall business strategy market economic trends events occur future cause us conclude impairment indicators exist certain intangible assets impaired financial condition results operations may adversely impacted fourth quarter recorded million impairment charges related certain iprd assets acquired cv therapeutics future plans develop deemed future use us market participants charges related gs adentri tecadenoson programs recorded rd expense majority impairment charge related gs program product candidate phase clinical studies treatment diabetes hypertriglyceridemia terminated fourth quarter due unfavorable results pharmacokinetics pharmacodynamics tests demonstrated limited effectiveness compound patients given results believe alternative future uses us market participants allowance doubtful accounts also maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required allowance doubtful accounts balance percentage total accounts receivable materially change december december believe allowance doubtful accounts adequate cover anticipated losses current conditions however significant deterioration factors could materially change expectations may result increase allowance doubtful accounts table contents prepaid royalties capitalize royalties prepaid cost specifically related emtricitabine royalties paid emory university emory hiv indication based present value future royalty obligation would expect pay emory assuming certain expected future levels product sales incorporating emtricitabine present value future royalty obligation derived using weightedaverage cost capital review periodically expected future sales levels products indicators might require writedown net recoverable value asset change estimated life prepaid royalty potential indicators impairment include launch significant product competitor significant deviations recognized product sales compared forecast product safety issues recalls amortize prepaid royalties based effective royalty rate derive forecasted future hiv product sales incorporating emtricitabine product sales forecasts prepared annually determined using best estimates future activity upon considering factors historical expected future patient usage uptake products introduction complimentary combination therapies products future product launch plans previously unanticipated significant change occurs sales forecasts including introduction competing product us one competitors hiv market emtricitabine prospectively update royalty rate used amortize prepaid royalties may increase future cost goods sold record amortization expense december prepaid royalty asset relating emtricitabine royalties paid emory million million respectively amortization expense relating prepaid royalty asset million million million years ended december respectively clinical trial accruals record accruals estimated clinical study costs clinical studies performed thirdparty contract research organizations cros costs significant component rd expenses incurred cro costs million million million respectively accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros validate accruals quarterly vendors perform detailed reviews activities related significant contracts based upon results validation processes assess appropriateness accruals make adjustments deem necessary ensure expenses reflect actual effort incurred cros generally significant portion total clinical trial costs associated start activities trial patient enrollment extensively outsource clinical trial activities usually perform small portion startup activities inhouse result cros typically perform total startup activities trials including document preparation site identification screening preparation prestudy visits training program management startup costs usually occur within months contract executed milestone event driven nature remaining clinical activities related costs patient monitoring administration generally occur ratably throughout life individual contract study contracts negotiated fixed per unit prices vary length three months single dose phase clinical study two years complex phase clinical study average length contracts upper end range order provide longterm safety efficacy data support commercial launches atripla truvada viread hepsera emtriva letairis ranexa material cro contracts terminable us upon written notice generally liable actual effort expended cro certain noncancelable expenses incurred point termination amounts paid advance relating uncompleted services refunded us contract terminated contracts may include additional termination payments become due payable terminate contract table contents additional termination payments recorded becomes probable contract terminated december differences actual estimated activity levels particular study material however management receive complete accurate information vendors underestimates activity levels associated study given point time may record additional potentially significant rd expenses future periods tax provision estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made future effective income tax rate may affected factors changes tax laws regulations rates changing interpretation existing laws regulations portion nontax deductible pharmaceutical excise tax required pay starting result enactment us healthcare reform legislation impact accounting stockbased compensation changes international organization changes overall levels income tax december total gross unrecognized tax benefits million million respectively total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification tax authorities around certain uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective tax authorities file federal state foreign income tax returns many jurisdictions united states abroad federal income tax purposes statute limitations open onward certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years california income tax purposes statute limitations remains open onwards income tax returns audited federal state foreign tax authorities currently examination internal revenue service tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return believe uncertain table contents tax positions currently pending material adverse effect consolidated financial statements although adverse resolution one uncertain tax positions period could material impact results operations period stockbased compensation measure sharebased payments employees directors including grants stock options based relative fair values fair values awards granted stock option plans employee stock purchase plan estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life stockbased compensation recognized expense requisite service periods consolidated statements income using graded vesting expense attribution approach unvested stock options granted prior january using straightline expense attribution approach stock options granted adoption new guidance sharebased payments employees directors january stockbased compensation expenses related stock options recognized adoption new guidance based awards ultimately expected vest gross expense reduced estimated forfeitures guidance requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates estimated forfeitures based historical experience prior adoption guidance pro forma information required disclosed included forfeitures occurred result guidance adopted january recognize tax benefit stockbased compensation additional paidin capital apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statements income rather apic years ended december recognized stockbased compensation expenses million million million respectively operating expenses capitalized million million million respectively inventory december unrecognized stockbased compensation expenses million related unvested stock options expect expense estimated weighted average period years management discussed development selection disclosure critical accounting policies audit committee board audit committee reviewed disclosure presented relating critical accounting policies results operations total revenues total revenues billion billion billion included total revenues product sales royalty revenues contract revenues significant percentage product sales continued denominated foreign currencies face exposure adverse movements foreign currency exchange rates used foreign currency exchange forward option contracts hedge percentage forecasted international sales primarily denominated euro foreign currency exchange unfavorable impact million revenues compared table contents product sales following table summarizes period period changes product sales thousands change change antiviral products atripla truvada viread hepsera emtriva total antiviral products ambisome letairis ranexa total product sales total product sales increased compared compared due primarily overall increase antiviral product sales driven strong growth atripla sales continued growth truvada sales growth cardiovascular products letairis ranexa also contributed overall increase product sales periods antiviral products antiviral product sales increased compared compared atripla atripla sales increased compared driven primarily sales volume growth united states europe atripla sales increased compared driven primarily sales volume growth united states europe european growth benefited launch atripla france second quarter atripla sales include efavirenz component gross margin zero efavirenz portion atripla sales approximately billion million million respectively atripla sales accounted total antiviral product sales respectively truvada truvada sales increased compared driven primarily sales volume growth united states europe truvada sales increased compared driven primarily sales volume growth united states europe partially offset unfavorable foreign currency exchange impact truvada sales accounted total antiviral product sales respectively antiviral products antiviral product sales include product sales viread hepsera emtriva decreased compared compared due primarily sales volume decreases hepsera partially offset sales volume increases viread ambisome sales ambisome increased compared compared driven primarily sales volume growth certain markets outside united states partially offset table contents unfavorable foreign currency exchange impact ambisome product sales united states canada relate solely sales ambisome astellas pharma us inc recorded manufacturing cost letairis sales letairis increased compared compared driven primarily sales volume growth united states ranexa sales ranexa increased compared driven primarily sales volume growth united states ranexa sales million million ranexa sales began april date gilead acquired cv therapeutics expect total product sales continue grow continue expand sales marketing efforts support continued opportunities market expansion royalty revenues following table summarizes period period changes royalty revenues thousands change change royalty revenues significant source royalty revenues sales tamiflu roche recognize royalties tamiflu sales roche quarter following quarter tamiflu sold royalty revenues million increase compared royalty revenues include royalties gsk hepsera royalties astellas us llc lexiscan royalties japan tobacco truvada contributed increase total royalty revenues tamiflu royalties roche contributed million total royalty revenues compared million pandemic planning initiatives worldwide began decline throughout royalty revenues million increase compared driven primarily recognition tamiflu royalties roche million compared tamiflu royalties roche million higher tamiflu royalties due increased tamiflu sales roche related primarily pandemic planning initiatives worldwide cost goods sold product gross margin following table summarizes period period changes product sales thousands cost goods sold thousands product gross margin change change total product sales cost goods sold product gross margin product gross margin consistent product gross margin product gross margin decreased due primarily higher proportion atripla sales gross margin zero efavirenz component well amortization associated intangible assets acquired acquisition cv therapeutics table contents expect product gross margin lower compared due primarily higher proportion expected atripla sales restructuring expenses second quarter approved communicated plan close research operations durham north carolina consolidate liver disease research activities foster city california believe plan allow employees collaborate effectively advance programs liver disease area year recorded total million million sga expenses rd expenses respectively related employee severance facilitiesrelated expenses plan december closed operations durham expect incur additional significant costs connection plan second quarter approved plan realize certain synergies result cv therapeutics acquisition realigning cardiovascular operations eliminating redundancies recorded million million restructuring expenses sga rd expenses respectively related employee severance relocation lease termination costs facilitiesrelated expenses total costs incurred plan million million sga rd expenses respectively expect incur additional costs connection plan research development expenses following table summarizes period period changes rd expenses thousands change change research development rd expenses consist primarily personnel costs including salaries benefits stockbased compensation clinical studies performed contract research organizations materials supplies licenses fees milestone payments collaboration arrangements overhead allocations consisting various support facilitiesrelated costs rd expenses increased million compared due primarily impairment charges million recorded related iprd assets acquired cv therapeutics million clinical studies expenses related increased hiv research activities million compensation benefits expenses majority impairment charge related gs program product candidate phase clinical studies treatment diabetes hypertriglyceridemia terminated fourth quarter due unfavorable results pharmacokinetics pharmacodynamics tests demonstrated limited effectiveness compound patients given results believe alternative future uses us market participants increase rd expenses partially offset million due timing certain clinical studies million lower rd expense reimbursement related collaboration tibotec rd expenses increased million compared due primarily increased compensation benefits expenses million driven higher headcount related growth business rd expense reimbursement related collaboration tibotec million increased clinical study expenses million increase compensation benefits expenses also driven severance termination benefits associated restructuring activities related acquisition cv therapeutics expect rd expenses increase levels due increased spending internal collaborative rd efforts anticipate product candidates progress advanced clinical studies well adding clinical development programs pipeline table contents selling general administrative expenses following table summarizes period period changes sga expenses thousands change change selling general administrative sga expenses increased million compared due primarily increased compensation benefits expenses million result higher headcount support expanding commercial activities increased contract professional services expenses million driven primarily expanding sales marketing activities million related facilities equipment expenses sga expenses increased million compared due primarily increased compensation benefits expenses million driven higher headcount related growth business increased contract professional services expenses million driven primarily expanding sales marketing activities million related certain contract termination costs increase compensation benefits expenses also driven severance termination benefits associated restructuring activities related acquisition cv therapeutics expect sga expenses increase levels due increased investment support continued growth franchises believe appropriate infrastructure support growth business interest income net recorded interest income net million million million respectively increase interest income net compared due primarily decreased costs related hedging activities decrease interest income net compared due primarily decreased interest income million driven reduction average yield investment portfolio result lower interest rates partially offset increase net foreign currency exchange gains million interest expense interest expense million million million respectively increase interest expense compared due primarily issuance convertible senior notes billion net issuance costs july increase interest expense compared due primarily effect accreting debt discount convertible notes due additional interest expense expected life debt result adopting certain accounting guidance provision income taxes provision income taxes billion million million respectively effective tax rate differed us federal statutory rate due primarily tax credits certain operating earnings nonus subsidiaries considered indefinitely invested outside united states partially offset state taxes provide us income taxes undistributed earnings foreign operations intended permanently reinvested effective tax rate differed us federal statutory rate due primarily tax credits resolution certain tax positions tax authorities certain operating earnings nonus subsidiaries considered indefinitely invested outside united states partially offset state taxes revaluation certain state tax assets related integration cv therapeutics table contents effective tax rate differs us federal statutory rate due primarily tax credits resolution certain tax positions tax authorities certain operating earnings nonus subsidiaries considered indefinitely invested outside united states partially offset state taxes liquidity capital resources following table summarizes cash cash equivalents marketable securities working capital cash flow activities end periods presented thousands december cash cash equivalents marketable securities working capital year ended december cash provided used operating activities investing activities financing activities cash cash equivalents marketable securities cash cash equivalents marketable securities totaled billion december increase billion december increase primarily attributable net cash provided operations billion proceeds billion issuance convertible senior notes net issuance costs partially offset billion used repurchase common stock stock repurchase programs cash cash equivalents marketable securities totaled billion december increase million december increase primarily attributable net cash provided operations billion proceeds issuances common stock employee stock plans million partially offset following cash used acquire cv therapeutics billion net cash cash equivalents marketable securities acquired cv therapeutics million million used repurchase common stock stock repurchase program million used extinguish convertible senior notes assumed acquisition cv therapeutics working capital working capital billion december increase million working capital december increase primarily attributable increase million cash cash equivalents shortterm marketable securities table contents increase million accounts receivable net primarily driven increased product sales increase million inventories due primarily purchase efavirenz estimated net selling price bristolmyers squibb company bms increase partially offset increase million current portion convertible senior notes net longterm obligations due reclassification convertible senior notes due current liabilities working capital billion december decrease million working capital december decrease primarily attributable increase million accounts payable due primarily purchase efavirenz estimated net selling price bms decrease million cash cash equivalents shortterm marketable securities since held higher proportion longterm marketable securities december compared december decrease partially offset increase million accounts receivable net driven primarily increased product sales cash provided operating activities cash provided operating activities billion primarily related net income billion adjusted noncash items million depreciation amortization expenses million stockbased compensation expenses million iprd impairment expenses million tax benefits employee stock plans partially offset million net cash outflow related changes operating assets liabilities million excess tax benefits stock option exercises reclassified cash used financing activities cash provided operating activities billion primarily related net income billion adjusted noncash items million stockbased compensation expenses million amortization expenses result adoption guidance joint ventures bms january reclassified change noncontrolling interest cash provided operating activities cash used financing activities cash provided operating activities billion primarily related net income billion adjusted noncash items million tax benefits employee stock plans million stockbased compensation expenses partially offset million excess tax benefits stock option exercises reclassified cash used financing activities cash used investing activities cash used investing activities billion driven net use billion purchases marketable securities million used acquisition cgi million capital expenditures cash used investing activities billion driven cash used acquisition cv therapeutics billion net cash acquired net use million purchases marketable securities million capital expenditures year capital expenditures included purchase office building approximately acres land located foster city california cash used investing activities million driven primarily net use million purchases marketable securities million capital expenditures year table contents cash used financing activities cash used financing activities billion driven primarily billion used repurchase common stock stock repurchase programs million used purchase note hedges related convertible senior notes due cash outflows partially offset billion proceeds issuance convertible senior notes net issuance costs million proceeds sale warrants related convertible senior notes million proceeds issuances common stock employee stock plans cash used financing activities billion driven primarily million used repurchase common stock stock repurchase program million used extinguish convertible senior notes assumed acquisition cv therapeutics cash outflows partially offset proceeds million issuances common stock employee stock plans cash used financing activities billion driven primarily billion used repurchase common stock stock repurchase program cash outflows partially offset proceeds million received issuances common stock employee stock plans well million excess tax benefits stock option exercises information current threeyear billion stock repurchase program authorized board may repurchased billion common stock december december remaining authorized amount stock repurchases may made billion repurchase program billion may completed billion stock repurchase program previously authorized board january year utilized total billion cash repurchase retire million shares common stock average purchase price per share january board authorized additional threeyear billion stock repurchase program commence upon completion existing program authorized may intend use additional authorization repurchase shares time time offset dilution created shares issued employee stock plans repurchase shares opportunistically amended restated credit agreement along whollyowned subsidiary gilead biopharmaceutics ireland corporation may borrow aggregate billion revolving credit loans credit agreement also includes subfacility swingline loans letters credit year borrowed repaid million loan revolving credit facility loans credit agreement bear interest interest rate either libor plus margin ranging basis points basis points base rate described credit agreement credit agreement terminate december unpaid borrowings thereunder shall due payable time may reduce commitments may prepay loans credit agreement whole part without penalty subject certain conditions december approximately billion available drawn credit agreement july issued billion convertible senior notes private placement purchased convertible note hedges well sold warrants net cost million cost convertible note hedges tax deductible life notes convertible note hedges warrants intended reduce potential economic dilution upon future conversions notes effectively increasing conversion prices notes used continue use net proceeds issuance convertible notes repurchase shares common stock repay existing indebtedness believe existing capital resources supplemented cash generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including limited following commercial performance current future products table contents progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities administrative expenses possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products establishment additional collaborative relationships companies costs associated defense settlement adverse results litigation government investigations may future require additional funding could form proceeds equity debt financings funding required assure available us favorable terms balance sheet arrangements balance sheet arrangements contractual obligations contractual obligations consist debt obligations operating leases capital commitments purchase obligations active pharmaceutical ingredients inventoryrelated items clinical trials contracts following table summarizes significant enforceable legally binding obligations future commitments obligations related contracts likely continue regardless fact certain obligations may cancelable december thousands payments due period less one contractual obligations total year years years years convertible senior notes operating lease obligations capital commitments purchase obligations clinical trials total convertible senior note obligations include future interest payments based fixed rate notes due notes due notes due notes due december carrying value convertible senior notes billion december firm capital project commitments approximately million primarily relating enterprise software purchase commitments facilities improvement projects december firm purchase commitments related active pharmaceutical ingredients certain inventoryrelated items amounts include minimum purchase requirements actual purchases expected significantly exceed amounts addition committed make potential future milestone payments third parties part licensing collaboration development arrangements payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded consolidated balance sheets included table table contents december several clinical studies various clinical trial phases significant clinical trial expenditures cros although material contracts cros cancelable historically cancelled contracts amounts reflect commitments based existing contracts reflect future modifications terminations existing contracts anticipated potential new contracts total gross unrecognized tax benefit liabilities including interest penalties million december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification tax authorities around certain uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective tax authorities amounts included longterm income taxes payable non current deferred tax assets consolidated balance sheet included table recent accounting pronouncements october financial accounting standards board issued new standards revenue recognition agreements multiple deliverables new standards impact determination individual deliverables included multiple element arrangement may treated separate units accounting additionally new standards modify manner transaction consideration allocated across separately identified deliverables longer permitting residual method allocating arrangement consideration new standards effective us beginning first quarter however early adoption permitted adoption standards material impact consolidated financial statements december response pharmaceutical excise tax mandated healthcare reform legislation adopted united states fasb issued new standard address pharmaceutical manufacturers recognize classify tax income statements effective along pharmaceutical manufacturers branded drug products required pay portion pharmaceutical excise tax calculated based select government sales preceding calendar year percentage total industry government sales new standard clarifies pharmaceutical excise tax shall presented operating expense liability related tax shall estimated recorded full upon first qualifying sale corresponding deferred cost amortized expense generally using straightline method allocation new standard effective us beginning first quarter estimate impact pharmaceutical excise tax million classified sga expense consolidated financial statements also december fasb issued update existing standard business combinations address pro forma financial disclosure requirements business combinations updated standard specifies public entity presents comparative financial statements entity disclose pro forma revenue earnings combined entity though business combination occurred current year occurred beginning comparable prior annual reporting period updated standard effective us beginning first quarter however early adoption permitted adoption standard material impact consolidated financial statements item quantitative qualitative disclosures market risk foreign currency exchange risk operations include manufacturing sales activities united states canada ireland well sales activities countries outside united states including europe asia pacific result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies table contents significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business significant percentage product sales denominated foreign currencies enter foreign currency exchange forward option contracts partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged following table summarizes notional amounts weightedaverage currency exchange rates fair values open foreign currency exchange forward contracts december foreign currency exchange option contracts outstanding december contracts maturities months less weightedaverage rates stated terms amount us dollars per foreign currency fair values represent estimated settlement amounts december notional amounts fair values us dollars thousands foreign currency exchange forward contracts weighted average notional settlement currency amount price fair value euro british pound canadian dollar australian dollar swiss franc danish krone swedish krone norwegian krone new zealand dollar turkish lira polish zloty total total notional amount billion total fair value relating net asset million open foreign currency exchange forward contracts december comparable total notional amount billion total fair value relating net liability million open foreign currency exchange forward contracts december interest rate risk portfolio availableforsale marketable securities fixed variable rate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based credit rating maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return table contents following table summarizes expected maturities average interest rates interestgenerating assets interestbearing liabilities december dollars thousands years ending december total fair value december thereafter total assets availableforsale debt securities average interest rate liabilities convertible senior notes average interest rate april issued convertible senior notes due notes notes private placement pursuant rule securities act amended notes issued par bear interest rates notes notes respectively may converted shares common stock subject certain circumstances july issued convertible senior notes due notes notes private placement pursuant rule securities act amended notes issued par bear interest rates notes notes respectively may converted shares common stock subject certain circumstances credit risk december held approximately million auction rate securities within availableforsale longterm marketable securities auction rate securities comprised approximately total cash cash equivalents marketable securities december began observing failed auctions auction rate securities underlying assets comprised student loans auction rate securities including subject failed auctions currently rated aaa consistent high quality rating required investment policy supported federal government part federal family education loan program overcollateralized auction rate securities reset every seven days maturity dates ranging annual interest rates ranging december auction rate securities continued earn interest auctions continue fail securities invested may unable liquidate auction rate securities par need desire access funds invested securities however based total cash marketable securities position expected operating cash flows well access funds credit facility believe able hold securities recovery auction market related securities may final maturity result anticipate current illiquidity auction rate securities material effect cash requirements working capital light volatility developments seen financial markets continue review cash equivalents marketable securities carefully strive invest prudently believe maintaining primary goals investment policy safety preservation principal diversification risk well liquidity helped protect us many risks credit markets allowing us continue meet operating cash flow requirements well execute strategic opportunities also subject credit risk accounts receivable related product sales accounts receivable balance december billion compared billion december majority trade accounts receivable arises product sales united states europe date table contents experienced significant losses respect collection accounts receivable believe allowance doubtful accounts adequate december item financial statements supplementary data financial statements required item set forth beginning annual report incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness disclosure controls procedures defined rule ae securities exchange act amended exchange act controls procedures company designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified securities exchange commissions rules forms information accumulated communicated companys management including chief executive officer chief financial officer appropriate allow timely decisions regarding required disclosure based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective december b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af exchange act internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included annual report issued report effectiveness internal control financial reporting december report audit internal control financial reporting appears c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited gilead sciences incs internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso criteria gilead sciences incs management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion gilead sciences inc maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated financial statements gilead sciences inc report dated february expressed unqualified opinion thereon ernst young llp palo alto california february table contents item b information applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed securities exchange commission pursuant regulation connection annual meeting stockholders proxy statement headings nominees director standing reelection qualification nominees board committees meetings executive officers section beneficial ownership reporting compliance written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website httpwwwgileadcom investors section corporate governance changes waivers code ethics disclosed website intend satisfy disclosure requirement item form k regarding amendment waiver provision code ethics disclosing information website item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee interlocks insider participation compensation committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference sections proxy statement headings security ownership certain beneficial owners management securities authorized issuance equity compensation plans item certain relationships related transactions director independence information required item incorporated reference sections proxy statement headings nominees director standing reelectionand certain relationships related party transactions item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services table contents part iv item exhibits financial statement schedules following documents filed part annual report index list consolidated financial statements report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements stockholders equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference exhibit exhibit footnote number description document agreement plan merger among registrant apex merger sub inc cv therapeutics inc dated march agreement plan merger among registrant cougar merger sub inc cgi pharmaceuticals inc dated june agreement plan merger among registrant arroyo merger sub inc arresto biosciences inc dated december stockholder agreement registrant louis g lange dated march restated certificate incorporation registrant amended may certificate designation series junior participating preferred stock registrant certificate amendment certificate designation series junior participating preferred stock registrant amended restated bylaws registrant amended restated october reference made exhibit exhibit exhibit exhibit amended restated rights agreement registrant chasemellon shareholder services llc dated october first amendment amended restated rights agreement registrant mellon investor services llc formerly known chasemellon shareholder services llc dated october second amendment amended restated rights agreement registrant mellon investor services llc formerly known chasemellon shareholder services llc dated may table contents exhibit exhibit footnote number description document indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated april indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated april indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated july indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated july confirmation otc convertible note hedge related notes dated april amended restated april registrant bank america na confirmation otc convertible note hedge related notes dated april amended restated april registrant bank america na confirmation otc warrant transaction dated april amended restated april registrant bank america na warrants expiring confirmation otc warrant transaction dated april amended restated april registrant bank america na warrants expiring amended restated credit agreement among registrant gilead biopharmaceutics ireland corporation lenders parties thereto bank america na administrative agent swing line lender lc issuer dated december parent guaranty agreement dated december registrant amendment amended restated credit agreement limited consent waiver dated june among registrant gilead biopharmaceutics ireland corporation bank america na capacity administrative agent lenders amendment amended restated credit agreement among registrant gilead biopharmaceutics ireland corporation bank america na capacity administrative agent lenders dated december confirmation otc convertible note hedge related notes dated july registrant goldman sachs co confirmation otc convertible note hedge related notes dated july registrant jpmorgan chase bank national association confirmation otc convertible note hedge related notes dated july registrant goldman sachs co confirmation otc convertible note hedge related notes dated july registrant jpmorgan chase bank national association confirmation otc warrant transaction dated july registrant goldman sachs co warrants expiring table contents exhibit exhibit footnote number description document confirmation otc warrant transaction dated july registrant jpmorgan chase bank national association warrants expiring confirmation otc warrant transaction dated july registrant goldman sachs co warrants expiring confirmation otc warrant transaction dated july registrant jpmorgan chase bank national association warrants expiring confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association confirmation otc additional warrant transaction dated august registrant goldman sachs co warrants expiring confirmation otc additional warrant transaction dated august registrant jpmorgan chase bank national association warrants expiring confirmation otc additional warrant transaction dated august registrant goldman sachs co warrants expiring confirmation otc additional warrant transaction dated august registrant jpmorgan chase bank national association warrants expiring amendment confirmation otc convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc convertible note hedge related notes dated august registrant jpmorgan chase bank national association amendment confirmation otc convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc convertible note hedge related notes dated august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association amendment confirmation otc additional convertible note hedge related notes dated august registrant goldman sachs co amendment confirmation otc additional convertible note hedge related notes dated august registrant jpmorgan chase bank national association gilead sciences inc stock option plan amended january form option agreements used stock option plan table contents exhibit exhibit footnote number description document gilead sciences inc nonemployee directors stock option plan amended january form option agreement used gilead sciences inc nonemployee directors stock option plan gilead sciences inc equity incentive plan amended may form employee stock option agreement used equity incentive plan grants prior february form employee stock option agreement used equity incentive plan grants made february april form employee stock option agreement used equity incentive plan grants commencing may form employee stock option agreement used equity incentive plan grants commencing february form nonemployee director stock option agreement used equity incentive plan grants prior form nonemployee director option agreement used equity incentive plan initial grants made form nonemployee director option agreement used equity incentive plan annual grants made may form nonemployee director option agreement used equity incentive plan annual grants commencing may form restricted stock unit issuance agreement used equity incentive plan annual grants nonemployee directors commencing may form restricted stock award agreement used equity incentive plan annual grants certain nonemployee directors form performance share award agreement used equity incentive plan grants made form performance share award agreement used equity incentive plan grants made form performance share award agreement used equity incentive plan grants made form performance share award agreement used equity incentive plan grants made form restricted stock unit issuance agreement used equity incentive plan grants made prior may form restricted stock unit issuance agreement used equity incentive plan grants commencing may form restricted stock unit issuance agreement used equity incentive plan servicebased vesting executive officers commencing november gilead sciences inc employee stock purchase plan amended restated november gilead sciences inc international employee stock purchase plan adopted november table contents exhibit exhibit footnote number description document gilead sciences inc deferred compensation planbasic plan document gilead sciences inc deferred compensation planadoption agreement addendum gilead sciences inc deferred compensation plan gilead sciences inc deferred compensation plan amended restated october gilead sciences inc severance plan amended december gilead sciences inc corporate bonus plan gilead sciences inc code section bonus plan base salaries named executive officers offer letter dated april registrant robin washington form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees form employee proprietary information invention agreement entered registrant certain officers key employees revised september amended restated collaboration agreement among registrant gilead holdings llc bristolmyers squibb company er squibb sons llc bristolmyers squibb gilead sciences llc dated september commercialization agreement gilead sciences limited bristolmyers squibb company dated december amendment agreement dated october registrant institute organic chemistry biochemistry iocb rega stichting vzw rega together following exhibits license agreement dated december registrant iocb rega license agreement license agreement dated october registrant iocb rega october license agreement license agreement dated december registrant iocb rega december license agreement amendment agreement registrant iocbrega dated december amending license agreement december license agreement sixth amendment agreement license agreement iocbrega registrant dated august amending october license agreement december license agreement development license agreement among registrant f hoffmannla roche ltd hoffmannla roche inc dated september first amendment supplement dated november development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc dated september exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may table contents exhibit exhibit footnote number description document royalty sale agreement among registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july amended restated license agreement registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july license agreement japan tobacco inc registrant dated march license agreement registrant successor myogen inc abbott deutschland holding gmbh dated october license agreement registrant successor cv therapeutics inc syntex usa inc dated march first amendment license agreement registrant successor cv therapeutics inc syntex usa inc dated july amendment license agreement registrant successor cv therapeutics inc syntex usa inc dated november amendment collaboration license agreement registrant successor cv therapeutics inc roche palo alto llc successor interest merger syntex usa inc dated june license collaboration agreement among registrant gilead sciences limited tibotec pharmaceuticals dated july master clinical commercial supply agreement gilead world markets limited registrant patheon inc dated january tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated july addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated may addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated december tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited ampac fine chemicals llc dated november restated amended toll manufacturing agreement gilead sciences limited registrant nycomed gmbh formerly altana pharma oranienburg gmbh dated november emtricitabine manufacturing supply agreement gilead sciences limited degussa ag dated june amendment emtricitabine manufacturing supply agreement gilead sciences limited evonik degussa gmbh formerly known degussa ag dated april purchase sale agreement escrow instructions electronics imaging inc registrant dated october table contents exhibit exhibit footnote number description document subsidiaries registrant consent independent registered public accounting firm power attorney reference made signature certification chief executive officer required rule aa rule da securities exchange act amended certification chief financial officer required rule aa rule da securities exchange act amended certifications chief executive officer chief financial officer required rule ab rule db section chapter title united states code usc following materials registrants annual report year ended december formatted extensible business reporting language xbrl includes consolidated balance sheets december ii consolidated statements income years ended december iii consolidated statements stockholders equity years ended december iv consolidated statements cash flows years ended december v notes consolidated financial statements filed exhibit registrants current report form k filed march incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants current report form k filed november incorporated herein reference filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form filed june incorporated herein reference filed exhibit registrants current report form k filed april incorporated herein reference filed exhibit registrants current report form k filed august incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants current report form k also filed december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference table contents filed exhibit registrants registration statement form amended incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants current report form ka filed february incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants current report form k first filed december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants registration statement form filed december incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference information included registrants current report form k filed january incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants annual report fiscal year ended march incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form qa filed november incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit myogen incs registration statement form amended originally filed august incorporated herein reference filed exhibit cv therapeutics incs registration statement form amended originally filed april incorporated herein reference filed exhibit cv therapeutics incs quarterly report form q quarter ended june incorporated herein reference table contents filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants current report form k filed august incorporated herein reference agreement plan merger merger agreement contains representations warranties registrant cougar merger sub inc cgi pharmaceuticals inc made solely specific dates representations warranties made solely purposes merger agreement may subject important qualifications limitations agreed registrant cougar merger sub inc cgi pharmaceuticals inc moreover representations warranties may accurate complete specified date may subject standard materiality provided merger agreement used purpose allocating risk among registrant cougar merger sub inc cgi pharmaceuticals inc rather establishing matters facts agreement plan merger merger agreement contains representations warranties registrant arroyo merger sub inc arresto biosciences inc made solely specific dates representations warranties made solely purposes merger agreement may subject important qualifications limitations agreed registrant arroyo merger sub inc arresto biosciences inc moreover representations warranties may accurate complete specified date may subject standard materiality provided merger agreement used purpose allocating risk among registrant arroyo merger sub inc arresto biosciences inc rather establishing matters facts management contract compensatory plan arrangement certification accompanies form q relates deemed filed securities exchange commission incorporated reference filing registrant securities act amended securities exchange act amended whether made date form q irrespective general incorporation language contained filing xbrl information furnished filed part registration statement prospectus purposes sections securities exchange act amended deemed filed purposes section securities exchange act amended otherwise subject liability sections certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary sec without mark pursuant registrants application requesting confidential treatment rule b securities exchange act amended table contents gilead sciences inc consolidated financial statements years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements stockholders equity consolidated statements cash flows notes consolidated financial statements table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements income stockholders equity cash flows three years period ended december audits also included financial statement schedule listed index item financial statements schedule responsibility companys management responsibility express opinion financial statements schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity us generally accepted accounting principles also opinion related financial statement schedule considered relation basic financial statements taken whole presents fairly material respects information set forth therein discussed note consolidated financial statements company changed method accounting business combinations effective january also audited accordance standards public company accounting oversight board united states gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion thereon ernst young llp palo alto california february table contents gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents shortterm marketable securities accounts receivable net allowances december december inventories deferred tax assets prepaid taxes prepaid expenses current assets total current assets property plant equipment net noncurrent portion prepaid royalties noncurrent deferred tax assets longterm marketable securities intangible assets noncurrent assets total assets liabilities stockholders equity current liabilities accounts payable accrued government rebates accrued compensation employee benefits income taxes payable accrued liabilities deferred revenues current portion convertible senior notes net longterm obligations total current liabilities longterm deferred revenues convertible senior notes net longterm income taxes payable longterm obligations commitments contingencies note stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december respectively additional paidin capital accumulated comprehensive income loss retained earnings total gilead stockholders equity noncontrolling interest total stockholders equity total liabilities stockholders equity see accompanying notes table contents gilead sciences inc consolidated statements income thousands except per share amounts year ended december revenues product sales royalty revenues contract revenues total revenues costs expenses cost goods sold research development selling general administrative purchased inprocess research development total costs expenses income operations interest income net interest expense income provision income taxes provision income taxes net income net loss attributable noncontrolling interest net income attributable gilead net income per share attributable gilead common stockholdersbasic shares used per share calculationbasic net income per share attributable gilead common stockholdersdiluted shares used per share calculationdiluted see accompanying notes table contents gilead sciences inc consolidated statements stockholders equity thousands gilead stockholders equity common stock accumulated additional total paidin comprehensive retained noncontrolling stockholders shares amount capital income loss earnings interest equity balance december distributions noncontrolling interest net income loss unrealized loss availableforsale securities net tax foreign currency translation adjustment unrealized gain cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans stockbased compensation repurchases common stock balance december distributions noncontrolling interest net income loss unrealized gain availableforsale securities net tax foreign currency translation adjustment unrealized loss cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans stockbased compensation assumption stock options connection acquisition repurchases common stock balance december distributions noncontrolling interest net income loss unrealized gain availableforsale securities net tax foreign currency translation adjustment unrealized gain cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans stockbased compensation purchases convertible note hedges sale warrants deferred tax assets convertible note hedges equity portion convertible notes net issuance costs repurchases common stock balance december see accompanying notes table contents gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income adjustments reconcile net income net cash provided operating activities depreciation expense amortization expense purchased inprocess research development expense stockbased compensation expenses inprocess research development impairment excess tax benefits stockbased compensation tax benefits employee stock plans deferred income taxes noncash transactions changes operating assets liabilities accounts receivable net inventories prepaid expenses assets accounts payable income taxes payable accrued liabilities deferred revenues net cash provided operating activities investing activities purchases marketable securities proceeds sales marketable securities proceeds maturities marketable securities acquisitions net cash acquired capital expenditures net cash used investing activities financing activities proceeds issuances convertible notes net issuance costs proceeds sale warrants purchases convertible note hedges proceeds credit facility repayments credit facility proceeds issuances common stock repurchases common stock extinguishment longterm debt repayments longterm obligations excess tax benefits stockbased compensation distributions noncontrolling interest net cash used financing activities effect exchange rate changes cash net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid income taxes paid see accompanying notes table contents gilead sciences inc notes consolidated financial statements organization summary significant accounting policies overview gilead sciences inc gilead us incorporated delaware june biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need mission advance care patients suffering life threatening diseases worldwide headquartered foster city california operations north america europe asia pacific market products hivaids liver disease respiratory cardiovascularmetabolic therapeutic areas product portfolio comprised atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg truvada emtricitabine tenofovir disoproxil fumarate viread tenofovir disoproxil fumarate emtriva emtricitabine treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil viread treatment chronic hepatitis b ambisome amphotericin b liposome injection treatment severe fungal infections letairis ambrisentan treatment pulmonary arterial hypertension pah ranexa ranolazine treatment chronic angina vistide cidofovir injection treatment cytomegalovirus infection cayston aztreonam inhalation solution treatment improve respiratory symptoms cystic fibrosis cf patients pseudomonas aeruginosa p aeruginosa addition also sell distribute certain products corporate partners royaltypaying collaborative agreements example f hoffmannla roche ltd together hoffmannla roche inc roche markets tamiflu oseltamivir phosphate treatment prevention influenza glaxosmithkline inc gsk markets hepsera viread treatment chronic hepatitis b certain territories outside united states gsk also markets volibris ambrisentan outside united states treatment pah astellas pharma us inc markets ambisome treatment severe fungal infections united states canada astellas us llc markets lexiscan regadenoson injection united states use pharmacologic stress agent radionuclide myocardial perfusion imaging mpi rapidscan pharma solutions inc markets rapiscan regadenoson certain territories outside united states inducement pharmacological stress andor vasodilation coronary vasculature strictly purposes diagnosing cardiovascular disease menarini international operations luxembourg sa markets ranexa certain territories outside united states treatment chronic angina japan tobacco inc japan tobacco markets truvada viread emtriva japan basis presentation accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries joint ventures bristol myers squibb company bms primary beneficiary record noncontrolling interest consolidated financial statements reflect bmss interest joint ventures intercompany transactions eliminated consolidated financial statements include results companies acquired us date acquisition applicable reporting periods consolidation variable interest entities january adopted amended guidance consolidation variable interest entities amended guidance eliminates mandatory quantitative approach determine whether variable interest gives entity controlling financial interest variable interest entity favor qualitatively focused analysis additionally amended guidance requires ongoing reassessment whether entity primary beneficiary adopted provisions guidance prospective basis joint ventures bms consolidate primary beneficiary adoption guidance impact consolidated financial statements table contents gilead sciences inc notes consolidated financial statementscontinued significant accounting policies estimates judgments preparation consolidated financial statements conformity us gaap requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis management evaluates estimates including critical accounting policies estimates related revenue recognition intangible assets allowance doubtful accounts prepaid royalties clinical trial accruals tax provision stockbased compensation base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates revenue recognition product sales recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectability reasonably assured upon recognition revenue product sales provisions made government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products appropriate items deducted gross product sales government rebates estimate reductions revenues governmentmanaged medicaid programs well certain qualifying federal state foreign government programs based contractual terms historical utilization rates new information regarding changes programs regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements government rebates invoiced directly us recorded accrued government rebates consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower contractual government price record allowances accounts receivable cash discounts estimate cash discounts based contractual terms historical utilization rates expectations regarding future utilization rates distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractually determined covenants maintenance agreed upon inventory levels distributor fees based contractually determined fixed percentage sales table contents gilead sciences inc notes consolidated financial statementscontinued product returns provide customers general right product return permit returns product damaged defective received customer case product sold unites states certain countries outside united states product expired accept returns product expire within six months prior expired one year expiration dates estimates expected returns expired products based primarily ongoing analysis historical return patterns royalty revenues royalty revenue sales lexiscan ambisome astellas us llc astellas pharma us inc respectively recognized month following month corresponding sales occur royalty revenue sales products generally recognized received generally quarter following quarter corresponding sales occur contract revenues revenue nonrefundable upfront license fees milestone payments development collaboration obligation supply product recognized performance occurs obligations completed accordance specific terms obligations arrangements revenue recognized obligation fulfilled ratably development manufacturing period revenue associated substantive atrisk milestones recognized based upon achievement milestones defined respective agreements advance payments received excess amounts earned classified deferred revenue consolidated balance sheets shipping handling costs shipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements income research development expenses major components research development rd expenses consist personnel costs including salaries benefits stockbased compensation clinical studies performed contract research organizations cros materials supplies licenses fees milestone payments collaboration arrangements overhead allocations consisting various support facilities related costs charge rd costs including clinical study costs expense incurred clinical study costs significant component rd expenses clinical studies performed thirdparty cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros validate accruals quarterly vendors perform detailed reviews activities related significant contracts based upon results validation processes assess appropriateness accruals make adjustments deem necessary ensure expenses reflect actual effort incurred cros material cro contracts terminable us upon written notice generally liable actual effort expended cro certain noncancelable expenses incurred point termination table contents gilead sciences inc notes consolidated financial statementscontinued amounts paid advance related uncompleted services refunded us contract terminated contracts may include additional termination payments become due payable terminate contract additional termination payments recorded becomes probable contract terminated advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding period diluted net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding dilutive securities outstanding period potential dilutive shares common stock resulting assumed exercise outstanding stock options restricted stock units performance shares assumed exercise warrants relating convertible senior notes due notes notes notes notes collectively notes determined treasury stock method principal amount notes settled cash conversion spread relating notes included calculation diluted net income per share attributable gilead common stockholders common stock resulting assumed settlement conversion spread notes dilutive effect average market price common stock period exceeds conversion prices notes notes notes notes respectively years ended average market prices common stock exceeded conversion prices notes dilutive effects included accompanying table warrants relating notes notes notes notes dilutive effect average market price common stock period exceeds warrants exercise prices respectively average market prices common stock years ended december exceed warrants exercise prices relating notes therefore warrants dilutive effect net income per share periods stock options purchase approximately million million million weightedaverage shares common stock outstanding years ended december respectively included computation diluted net income per share attributable gilead common stockholders effect antidilutive table contents gilead sciences inc notes consolidated financial statementscontinued following table reconciliation numerator denominator used calculation basic diluted net income per share attributable gilead common stockholders thousands year ended december numerator net income attributable gilead denominator weightedaverage shares common stock outstanding used calculation basic net income per share attributable gilead common stockholders effect dilutive securities stock options equivalents conversion spread related notes conversion spread related notes weightedaverage shares common stock outstanding used calculation diluted net income per share attributable gilead common stockholders stockbased compensation sharebased payments employees recognized consolidated statements income based fair values benefit tax deductions excess recognized compensation cost reported consolidated statements cash flows financing activity rather operating activity calculated pool excess tax benefits recorded part additional paidin capital apic cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents may enter overnight repurchase agreements repos purchase securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents investment policy may enter repos major banks authorized dealers provided repos collateralized us government securities fair value least fair value securities sold us eligible instruments investment policy included cash equivalents include commercial paper money market funds bank obligations marketable nonmarketable securities determine appropriate classification marketable securities consist primarily debt securities include auction rate securities variable rate demand obligations time purchase reevaluate designation balance sheet date marketable securities considered availableforsale carried estimated fair values reported either cash equivalents shortterm marketable securities longterm marketable securities unrealized gains losses availableforsale securities excluded net income reported accumulated comprehensive income loss separate component stockholders equity interest income net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities otherthantemporary declines fair value securities cost securities sold based specific table contents gilead sciences inc notes consolidated financial statementscontinued identification method regularly review investments otherthantemporary declines fair value review includes consideration cause impairment including creditworthiness security issuers number securities unrealized loss position severity duration unrealized losses whether intent sell securities whether likely required sell securities recovery amortized cost basis determine decline fair value investment accounting basis decline otherthan temporary reduce carrying value security hold record loss amount decline result entering collaborations time time may hold investments nonpublic companies record nonmarketable securities cost noncurrent assets less amounts otherthantemporary impairment regularly review securities indicators impairment investments nonmarketable securities material periods presented concentrations risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe date experienced significant losses respect collection accounts receivable believe allowance doubtful accounts adequate december certain raw materials components utilize operations obtained single suppliers certain raw materials utilize operations made one facility since suppliers key components raw materials must named new drug application nda filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship commercial products supply product candidates clinical trials accounts receivable trade accounts receivable recorded net allowances wholesaler chargebacks related government rebate programs cash discounts prompt payment doubtful accounts sales returns estimates wholesaler chargebacks government rebates cash discounts sales returns based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding geographic region review local economic environment potential impact government funding reimbursement practices historically amounts uncollectible accounts receivable written insignificant consistent managements expectations table contents gilead sciences inc notes consolidated financial statementscontinued inventories inventories recorded lower cost market cost determined firstin firstout basis periodically review composition inventories order identify obsolete slowmoving otherwise unsaleable items unsaleable items observed alternate uses inventory record writedown net realizable value period impairment first recognized prepaid royalties prepaid royalties capitalized cost initially equivalent present value future royalty obligation would expect pay licensor expected future levels product sales incorporating related technology review periodically expected future sales levels products indicators might require writedown net recoverable value asset change estimated life prepaid royalty amortize prepaid royalties cost goods sold remaining life underlying patent based effective royalty rate derived forecasted future product sales incorporating related technology review effective royalty rate least annually prospectively adjust effective rate based significant new facts circumstances may arise review prepaid royalties primarily comprised emtricitabine royalties paid emory university emory hiv indication royalty pharma purchased royalty interest owned emory terms transaction royalty pharma paid respectively total purchase price million emory exchange elimination emtricitabine royalties due emory worldwide net sales products containing emtricitabine result transaction capitalized prepaid royalties share million purchase price million december unamortized prepaid royalty asset million million respectively million million million amortized cost goods sold respectively property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straightline method repairs maintenance costs expensed incurred estimated useful lives years follows description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term office computer equipment includes capitalized software unamortized capitalized software costs million million consolidated balance sheets december respectively leasehold improvements capitalized leased equipment amortized shorter lease term assets useful life amortization capitalized leased equipment included depreciation expense capitalized interest construction inprogress included property plant equipment interest capitalized significant table contents gilead sciences inc notes consolidated financial statementscontinued goodwill intangible assets goodwill represents excess consideration transferred estimated fair value assets acquired liabilities assumed business combination intangible assets primarily related marketed products purchased inprocess research development iprd projects acquisitions cgi pharmaceuticals inc cgi july cv therapeutics inc cv therapeutics april measured respective fair values acquisition date amortize goodwill intangible assets indefinite useful lives test goodwill indefinitelived intangible assets impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value assets carrying amounts intangible assets finite useful lives amortized estimated useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable amortize intangible asset related ranexa acquired cv therapeutics estimated useful life using amortization rate derived forecasted future product sales ranexa product sales forecasts prepared annually determined using best estimates future activity consider factors historical expected future patient usage uptake products introduction complimentary combination therapies products future product launch plans previously unanticipated significant change occurs sales forecasts prospectively update rate used amortize intangible asset related ranexa may increase future cost goods sold record amortization expense amortize intangible asset related lexiscan also acquired cv therapeutics estimated useful life cost goods sold straightline basis given current lexiscan revenues consist royalties received collaboration partner lack ongoing access visibility partners future sales forecasts make reasonable estimate amortization rate using forecasted product sales approach impairment longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment fda another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated income producing asset indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset asset group eventual disposition carrying amount asset asset group excess carrying value asset asset group estimated fair value recognized impairment loss foreign currency translation transactions contracts adjustments resulting translating financial statements foreign subsidiaries us dollars excluded determination net income recorded accumulated comprehensive income loss separate component stockholders equity net foreign currency exchange transaction gains losses included interest income net consolidated statements income net transaction losses totaled million million million respectively table contents gilead sciences inc notes consolidated financial statementscontinued hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions limit risk counterparties contracts may unable perform also limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge net investment foreign subsidiaries fair value financial instruments financial instruments consist principally cash cash equivalents marketable securities accounts receivable foreign currency exchange forward option contracts accounts payable shortterm longterm debt cash cash equivalents marketable securities foreign currency exchange contracts hedge accounts receivable forecasted sales reported respective fair values consolidated balance sheets carrying value fair value notes billion billion respectively december carrying value fair value notes billion billion respectively december fair value notes based quoted market values remaining financial instruments reported consolidated balance sheets amounts approximate current fair values income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income taxes estimates based interpretations existing tax laws regulations various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates portion nontax deductible pharmaceutical excise tax required pay starting result enactment us healthcare reform legislation accounting stock options sharebased payments mergers acquisitions future levels rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact consolidated net income record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return believe uncertain tax positions currently pending material adverse effect consolidated financial statements although adverse resolution one uncertain tax positions period could material impact results operations period table contents gilead sciences inc notes consolidated financial statementscontinued recent accounting pronouncements october financial accounting standards board fasb issued new standards revenue recognition agreements multiple deliverables new standards impact determination individual deliverables included multiple element arrangement may treated separate units accounting additionally new standards modify manner transaction consideration allocated across separately identified deliverables longer permitting residual method allocating arrangement consideration new standards effective us beginning first quarter however early adoption permitted adoption standards material impact consolidated financial statements december response pharmaceutical excise tax mandated healthcare reform legislation adopted united states fasb issued new standard address pharmaceutical manufacturers recognize classify tax income statements effective along pharmaceutical manufacturers branded drug products required pay portion pharmaceutical excise tax calculated based select government sales preceding calendar year percentage total industry government sales new standard clarifies pharmaceutical excise tax shall presented operating expense liability related tax shall estimated recorded full upon first qualifying sale corresponding deferred cost amortized expense generally using straightline method allocation new standard effective us beginning first quarter estimate impact pharmaceutical excise tax million classified selling general administrative expense consolidated financial statements also december fasb issued update existing standard business combinations address pro forma financial disclosure requirements business combinations updated standard specifies public entity presents comparative financial statements entity disclose pro forma revenue earnings combined entity though business combination occurred current year occurred beginning comparable prior annual reporting period updated standard effective us beginning first quarter however early adoption permitted adoption standard material impact consolidated financial statements fair value measurements determine fair value financial nonfinancial assets liabilities using fair value hierarchy establishes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques well significant management judgment estimation table contents gilead sciences inc notes consolidated financial statementscontinued certain amounts within debt securities recategorized accompanying tables conform current presentation following table summarizes assets liabilities recorded fair value respective fair value classification level input within fair value hierarchy defined thousands december december level level level total level level level total assets debt securities us treasury securities usgovernment agencies fdic guaranteed securities municipal debt securities nonus government securities corporate debt securities residential mortgage assetbacked securities student loanbacked securities total debt securities equity securities derivatives liabilities contingent consideration derivatives marketable securities measured fair value using level inputs primarily comprised us government agencies fdic guaranteed securities corporate debt securities review trading activity pricing investments measurement date sufficient quoted pricing identical securities available use market pricing observable market inputs similar securities obtained various thirdparty data providers inputs either represent quoted prices similar assets active markets derived observable market data approach results level classification securities within fair value hierarchy table contents gilead sciences inc notes consolidated financial statementscontinued following table reconciliation marketable securities measured fair value using significant unobservable inputs level thousands year ended december balance beginning period total realized unrealized gains losses included interest income net comprehensive income net sales marketable securities transfers level balance end period total losses included interest income net attributable change unrealized losses relating assets still held reporting date policy recognize transfers level classification actual date event change circumstances caused transfer marketable securities measured fair value using level inputs substantially comprised auction rate securities within availableforsale investment portfolio underlying assets auction rate securities consist student loans although auction rate securities would typically measured using level inputs failure auctions lack market activity liquidity experienced since beginning required securities measured using level inputs fair value auction rate securities determined using discounted cash flow model considered projected cash flows issuing trusts underlying collateral expected yields projected cash flows estimated based underlying loan principal bonds outstanding payout formulas weightedaverage life cash flows projected considered collateral composition securities related historical projected prepayments underlying student loans weightedaverage expected life four eight years discount rates used discounted cash flow model based market conditions comparable similar term assetbacked fixed income securities adjusted illiquidity discount resulted annual discount rate auction rate securities reset every seven days maturity dates ranging annual interest rates ranging december auction rate securities continued earn interest auction rate securities recorded longterm marketable securities consolidated balance sheets december although continued failed auctions well lack market activity liquidity believe otherthantemporary impairments securities december intend sell securities likely required sell securities recovery amortized cost basis table contents gilead sciences inc notes consolidated financial statementscontinued availableforsale securities following table summary availableforsale debt equity securities recorded cash equivalents marketable securities consolidated balance sheets estimated fair values availableforsale securities generally based prices obtained commercial pricing services thousands gross gross amortized unrealized unrealized estimated cost gains losses fair value december debt securities us treasury securities us government agencies fdic guaranteed securities municipal debt securities nonus government securities corporate debt securities residential mortgage assetbacked securities student loanbacked securities total debt securities equity securities total december debt securities us treasury securities us government agencies fdic guaranteed securities municipal debt securities nonus government securities corporate debt securities residential mortgage assetbacked securities student loanbacked securities total debt securities equity securities total following table summarizes classification availableforsale debt equity securities consolidated balance sheets thousands december december cash cash equivalents shortterm marketable securities longterm marketable securities total table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes portfolio availableforsale debt securities contractual maturity thousands december december amortized amortized cost fair value cost fair value less one year greater one year less five years greater five years less ten years greater ten years total following table summarizes gross realized gains losses related sales marketable securities thousands year ended december gross realized gains sales gross realized losses sales cost securities sold determined based specific identification method table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes availableforsale debt securities continuous unrealized loss position deemed otherthan temporarily impaired thousands less months months greater total gross gross gross unrealized estimated unrealized estimated unrealized estimated losses fair value losses fair value losses fair value december debt securities us treasury securities us government agencies fdic guaranteed securities municipal debt securities nonus government securities corporate debt securities residential mortgage assetbacked securities student loanbacked securities total december debt securities us treasury securities us government agencies fdic guaranteed securities municipal debt securities nonus government securities corporate debt securities residential mortgage assetbacked securities student loanbacked securities total december approximately respectively total number securities unrealized loss position gross unrealized losses auction rate securities caused higher discount rate used valuation securities compared coupon rates securities gross unrealized losses securities primarily result increase yieldtomaturity underlying securities significant facts circumstances arisen indicate deterioration creditworthiness issuers securities based review securities believe otherthantemporary impairments securities december intend sell securities likely required sell securities recovery amortized cost basis table contents gilead sciences inc notes consolidated financial statementscontinued derivative financial instruments operate foreign countries exposes us market risk associated foreign currency exchange rate fluctuations us dollar various foreign currencies significant euro order manage risk hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions limit risk counterparties contracts may unable perform also limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge net investment foreign subsidiaries hedge exposure foreign currency exchange rate fluctuations certain monetary assets liabilities foreign subsidiaries denominated nonfunctional currency derivative instruments use hedge exposure designated hedges result changes fair value recorded interest income net consolidated statements income hedge exposure foreign currency exchange rate fluctuations forecasted product sales denominated nonfunctional currency derivative instruments use hedge exposure designated cash flow hedges maturity dates months less upon executing hedging contract quarterly thereafter assess prospective hedge effectiveness using regression analysis calculates change cash flow result hedge instrument monthly basis assess retrospective hedge effectiveness using dollar offset approach exclude time value effectiveness testing recognize changes time value hedge interest income net effective component hedge recorded unrealized gain loss hedging instrument accumulated comprehensive income oci within stockholders equity hedged forecasted transaction occurs hedge dedesignated unrealized gains losses reclassified product sales majority gains losses related hedged forecasted transactions reported accumulated oci december reclassified product sales within months notional amounts foreign currency exchange contracts outstanding billion billion december respectively table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes information fair values derivative instruments consolidated balance sheets thousands december asset derivatives liability derivatives location fair value location fair value derivatives designated hedges foreign currency exchange contracts current accrued assets liabilities foreign currency exchange contracts noncurrent longterm assets obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current accrued assets liabilities total derivatives designated hedges total derivatives december asset derivatives liability derivatives location fair value location fair value derivatives designated hedges foreign currency exchange contracts current accrued assets liabilities foreign currency exchange contracts noncurrent longterm assets obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current accrued assets liabilities total derivatives designated hedges total derivatives following table summarizes effect foreign currency exchange contracts consolidated statements income thousands year ended december derivatives designated hedges net gains losses recognized oci effective portion net gains reclassified accumulated oci product sales effective portion net gains losses recognized interest income net ineffective portion amounts excluded effectiveness testing derivatives designated hedges net gains losses recognized interest income net table contents gilead sciences inc notes consolidated financial statementscontinued acquisitions january adopted guidance recognizing measuring assets acquired liabilities assumed noncontrolling interests acquiree business combination guidance requires example iprd capitalized fair value intangible assets time acquisition acquisition related expenses restructuring costs recognized separately business combination adopted provisions guidance prospective basis applied acquisitions cgi cv therapeutics discussed cgi pharmaceuticals inc june entered agreement acquire cgi million cash consisting million upfront payment million contingent consideration payable based achievement clinical development milestones transaction closed july time cgi became whollyowned subsidiary cgi privatelyheld development stage pharmaceutical company based branford connecticut primarily focused small molecule chemistry protein kinase biology lead preclinical compound cgis library proprietary small molecule kinase inhibitors targets spleen tyrosine kinase syk could unique applications treatment serious inflammatory diseases including rheumatoid arthritis believe acquisition provides us opportunity expand research efforts interesting promising area drug discovery cgi acquisition accounted business combination results operations cgi since july included consolidated statements income significant acquisitiondate fair value total consideration transferred acquire cgi million consisted cash paid prior closing million contingent consideration million following table summarizes fair value assets acquired liabilities assumed july thousands intangible assetsiprd goodwill deferred tax assets deferred tax liabilities net liabilities assumed total consideration transferred intangible assets intangible assets associated inprocess research development iprd projects relate preclinical syk product candidate management estimated acquisitiondate fair value intangible assets related iprd million estimated fair value determined using income approach discounts expected future cash flows present value estimated fair value using present value discount rate based estimated weightedaverage cost capital companies profiles substantially similar cgi comparable estimated internal rate return cgis operations represents rate market participants would use value intangible assets projected cash flows iprd project based key assumptions estimates revenues operating profits related project considering stage development time resources needed complete development approval product candidate life potential commercialized product table contents gilead sciences inc notes consolidated financial statementscontinued associated risks including inherent difficulties uncertainties developing drug compound obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts period assets considered indefinitelived amortized tested impairment annual basis well annual tests become aware events occurring changes circumstances would indicate reduction fair value iprd projects respective carrying amounts development complete generally occurs regulatory approval market product obtained associated assets would deemed finitelived would amortized based respective estimated useful lives point time goodwill excess consideration transferred fair values assigned assets acquired liabilities assumed million represents goodwill amount resulting cgi acquisition management believes goodwill mainly represents synergies expected combining research development operations well acquiring cgis assembled workforce intangible assets qualify separate recognition recorded goodwill intangible asset consolidated balance sheet acquisition date goodwill tested impairment annual basis well annual tests become aware events occurring changes circumstances would indicate reduction fair value goodwill carrying amount elected treat cgi acquisition asset acquisition california state tax purposes goodwill resulting acquisition deductible california state income tax purposes although amounts deductible federal income tax purposes consider cgi acquisition material business combination therefore disclosed pro forma results operations required material business combinations cv therapeutics inc april acquired cv therapeutics cash tender offer terms agreement plan merger entered march cv therapeutics publiclyheld biopharmaceutical company based palo alto california primarily focused discovery development commercialization small molecule drugs treatment cardiovascular metabolic pulmonary diseases cv therapeutics two marketed products ranexa treatment chronic angina lexiscan injection use pharmacologic stress agent radionuclide mpi patients unable undergo adequate exercise stress cv therapeutics also several product candidates clinical development treatment cardiovascular metabolic pulmonary diseases cv therapeutics acquisition accounted business combination results operations cv therapeutics since april included consolidated statements income acquisition date determined april date acquired approximately outstanding shares common stock cv therapeutics obtained effective control company acquisition completed two days later april time cv therapeutics became whollyowned subsidiary aggregate consideration transferred acquire cv therapeutics billion consisted cash paid common stock equity instruments prior closing billion fair value vested stock options assumed million table contents gilead sciences inc notes consolidated financial statementscontinued accordance merger agreement number gilead stock options restricted stock units assumed cv therapeutics stock options restricted stock units converted determined based option conversion ratio conversion ratio calculated taking per share acquisition price dividing average closing price common stock five consecutive trading days immediately preceding including closing date april per share fair value stock options assumed calculated using blackscholes valuation model following assumptions market price per share closing price common stock acquisition date expected term ranging years riskfree interest rate ranging expected volatility ranging dividend yield fair value restricted stock units assumed calculated using acquisitiondate closing price per share common stock included fair value vested stock options assumed us million consideration transferred acquisition assume vested restricted stock units estimated fair value unvested stock options restricted stock units assumed us million included consideration transferred recognized stockbased compensation expenses remaining future vesting period awards following table summarizes assets acquired liabilities assumed april thousands intangible assetsmarketed products intangible assetsiprd goodwill deferred tax assets deferred tax liabilities assetsliabilities cash cash equivalents marketable securities accounts receivable inventories prepaids current assets property plant equipment assets accounts payable accrued current liabilities convertible senior notes liabilities total net liabilities total consideration transferred intangible assets substantial portion assets acquired consisted intangible assets related cv therapeutics two marketed products ranexa lexiscan cv therapeutics iprd projects management determined estimated acquisitiondate fair values intangible assets related marketed products iprd projects million million respectively table contents gilead sciences inc notes consolidated financial statementscontinued million intangible assets related marketed products million related ranexa million related lexiscan determined intangible assets finite useful lives amortized respective useful lives estimated periods associated product patents expire periods intangible assets expected contribute future cash flows related products amortizing intangible asset related ranexa estimated useful life using amortization rate derived forecasted future product sales ranexa amortizing intangible asset related lexiscan estimated useful life straightline basis given current lexiscan revenues consist royalties received collaboration partner lack ongoing access visibility partners future sales forecasts make reasonable estimate amortization rate using forecasted product sales approach weightedaverage amortization period intangible assets approximately ten years million intangible assets related iprd projects million related gs formerly cvt product candidate phase clinical studies treatment diabetes hypertriglyceridemia remaining balance intangible assets related iprd projects represented various inprocess projects single project comprising significant portion total value intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts period assets considered indefinitelived amortized tested impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value iprd projects respective carrying amounts fourth quarter recorded million impairment charges related certain iprd assets acquired cv therapeutics future plans develop deemed future use us market participants charges related gs adentri tecadenoson programs recorded rd expense majority impairment charge related gs program terminated fourth quarter due unfavorable results pharmacokinetics pharmacodynamics tests demonstrated limited effectiveness compound patients given results believe alternative future uses us market participants december million iprd assets acquired cv therapeutics remaining consolidated balance sheet deferred tax assets deferred tax liabilities million deferred tax assets resulting acquisition primarily related federal state net operating loss tax credit carryforwards million deferred tax liabilities resulting acquisition primarily related difference book basis tax basis intangible assets related marketed products iprd projects concluded likely realize benefit deferred tax assets related certain state net operating loss carryforwards result valuation allowance million recorded related deferred tax assets presentation purposes million deferred tax liabilities noncurrent nature netted noncurrent deferred tax assets consolidated balance sheet result impairment charges recorded fourth quarter reduced deferred tax liabilities related iprd projects million convertible senior notes result acquisition assumed convertible notes cv therapeutics consisting senior subordinated convertible notes due senior subordinated convertible notes due table contents gilead sciences inc notes consolidated financial statementscontinued senior subordinated convertible debentures due convertible notes recognized fair values acquisition date may offered repurchase convertible notes consideration par value plus accrued interest required terms respective convertible note agreements following occurrence change control fundamental change defined agreements december convertible notes extinguished goodwill excess consideration transferred fair values assigned assets acquired liabilities assumed million represents goodwill amount resulting acquisition management believes goodwill mainly represents synergies economies scale expected combining operations cv therapeutics none goodwill expected deductible income tax purposes recorded goodwill intangible asset consolidated balance sheet acquisition date goodwill tested impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value goodwill carrying amount navitas assets llc may executed asset purchase agreement navitas assets llc navitas acquire assets related cicletanine business acquired exclusive rights regulatory data filings development cicletanine monotherapy pah indications united states evaluating cicletanine currently phase clinical trials potential treatment pah aggregate consideration transferred acquisition million consisted primarily cash paid addition navitas entitled potential additional purchase consideration including payments contingent future achievement certain development regulatory milestones amounts recorded related contingencies resolved consideration transferred allocated iprd represents purchased iprd program cicletanine yet reached technological feasibility alternative future uses acquisition date therefore expensed upon acquisition within consolidated statement income restructuring second quarter implemented plan close research operations durham north carolina consolidate liver disease research activities foster city california restructuring plan includes consolidation liver disease rd organization exit certain facilities year recorded total million million sga expenses rd expenses respectively related employee severance facilitiesrelated expenses plan december closed operations durham expect incur additional significant costs connection plan second quarter approved plan realize certain synergies result cv therapeutics acquisition realigning cardiovascular operations eliminating redundancies restructuring plan included consolidation realignment cardiovascular rd organization exit certain facilities termination certain contractual obligations recorded million million restructuring expenses sga rd expenses respectively comparatively recorded million million sga rd expenses respectively years expenses primarily related employee severance relocation lease termination costs facilitiesrelated table contents gilead sciences inc notes consolidated financial statementscontinued expenses total costs incurred plan million million sga rd expenses respectively expect incur additional costs connection plan following table summarizes restructuring liabilities accrued changes amounts period restructuring plan related cardiovascular operations thousands employee severance facilities termination related benefits costs balance december costs incurred period costs paid settled period balance december costs incurred period costs paid settled period balance december inventories inventories summarized follows thousands december raw materials work process finished goods total inventories december joint ventures formed gilead bms see note included consolidated financial statements held million million inventory respectively efavirenz active pharmaceutical ingredient purchased bms bms estimated net selling price efavirenz table contents gilead sciences inc notes consolidated financial statementscontinued property plant equipment property plant equipment summarized follows thousands december property plant equipment net buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction progress subtotal less accumulated depreciation amortization including relating capitalized leased equipment respectively subtotal land total january completed purchase office building approximately acres land located foster city california aggregate purchase price million based estimated relative fair values purchase price allocated primarily land million building million land improvements million office furniture equipment million intangible assets following table summarizes carrying amount intangible assets thousands december goodwill finite lived intangible assets indefinite lived intangible assets total following table summarizes changes carrying amount goodwill thousands balance december goodwill resulting acquisition cgi balance december table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes finitelived intangible assets thousands december december gross carrying accumulated gross carrying accumulated amount amortization amount amortization intangible assetranexa intangible assetlexiscan total amortization expense related intangible assets million year ended december recorded cost goods sold consolidated statement income amortization expense related intangible assets million year ended december recorded primarily cost goods sold consolidated statement income amortization expense related intangible assets million year ended december recorded primarily sga expenses consolidated statement income weightedaverage amortization period intangible assets approximately ten years december estimated future amortization expense associated intangible assets five succeeding fiscal years follows thousands fiscal year amount total december indefinitelived intangible assets million consisted million million purchased iprd acquisitions cgi cv therapeutics respectively fourth quarter recorded million impairment charges related certain iprd assets acquired cv therapeutics future plans develop deemed future use us market participants charges related gs adentri tecadenoson programs recorded rd expense majority impairment charge related gs program product candidate phase clinical studies treatment diabetes hypertriglyceridemia terminated fourth quarter due unfavorable results pharmacokinetics pharmacodynamics tests demonstrated limited effectiveness compound patients given results believe alternative future uses us market participants december indefinitelived intangible assets million related purchased iprd acquisition cv therapeutics collaborative arrangements result entering strategic collaborations time time may hold investments nonpublic companies review interests investee companies consolidation andor appropriate disclosure based applicable guidance disclosed note determined certain investee table contents gilead sciences inc notes consolidated financial statementscontinued companies variable interest entities however respect joint ventures bms primary beneficiary therefore consolidate investees bristolmyers squibb company north america december entered collaboration arrangement bms united states develop commercialize singletablet regimen containing truvada bmss sustiva efavirenz sell atripla collaboration structured joint venture operates limited liability company named bristolmyers squibb gilead sciences llc consolidate ownership interests joint venture thus sharing product revenue costs reflect respective economic interests bms gilead based proportions net selling price atripla attributable efavirenz truvada since net selling price truvada may change time relative net selling price efavirenz bmss respective economic interests joint venture may vary annually share marketing sales efforts bms parties obligated provide equivalent sales force efforts minimum number years starting second quarter except limited number activities jointly managed parties longer coordinate detailing promotional activities united states parties continue collaborate activities manufacturing regulatory compliance pharmacovigilance responsible accounting financial reporting tax reporting manufacturing product distribution joint venture parties provide respective bulk active pharmaceutical ingredients joint venture approximate market values july joint venture received approval fda sell atripla united states september bms amended joint ventures collaboration agreement allow joint venture sell atripla canada october joint venture received approval health canada sell atripla canada december joint venture held efavirenz active pharmaceutical ingredient purchased bms bmss estimated net selling price efavirenz us market amounts included inventories consolidated balance sheets december total assets held joint venture billion billion respectively consisted primarily cash cash equivalents accounts receivable including intercompany receivables gilead inventories december total liabilities held joint venture million billion respectively consisted primarily accounts payable including intercompany payables gilead accrued expenses asset liability amounts reflect impact intercompany eliminations included consolidated balance sheets although primary beneficiary joint venture legal structure joint venture limits recourse creditors general credit assets europe december gilead sciences limited gsl whollyowned subsidiary ireland bms entered collaboration arrangement commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bmss estimated net selling price efavirenz european territory responsible product distribution inventory management warehousing local subsidiaries primary responsibility order fulfillment collection receivables customer relations handling sales returns territories copromote atripla bms also responsible accounting financial reporting tax reporting collaboration december table contents gilead sciences inc notes consolidated financial statementscontinued european commission approved atripla sale european union december efavirenz purchased bms bmss estimated net selling price efavirenz european territory included inventories consolidated balance sheets parties also formed limited liability company hold marketing authorization atripla europe primary responsibility regulatory activities share marketing sales efforts bms major market countries parties agreed provide equivalent sales force efforts revenue cost sharing based relative ratio respective net selling prices truvada efavirenz pari gmbh result acquisition corus pharma inc corus august assumed rights february development agreement corus pari gmbh pari development cayston development inhalation delivery device product terms agreement obligated pay pari services rendered subject achievement specific milestones obligated pay certain milestone payments pari addition make royalty payments based net sales cayston agreement also provided us right reduce royalty rate payable pari november paid pari million reduce royalty rate agreement cayston yet approved commercialization time payment recorded payment rd expenses consolidated statement income april pursuant february development agreement entered commercialization agreement pari provides supply manufacture inhalation delivery device accessories use cayston terms agreement obligated pay royalties future net sales products pursuant development agreement february received marketing approval fda cayston treatment improve respiratory symptoms cf patients p aeruginosa cayston conditionally approved europe canada september parion sciences inc august entered research collaboration license agreement parion sciences inc parion research develop commercialize certain epithelial sodium channel enac inhibitors treatment pulmonary diseases agreement granted us worldwide commercialization rights gs formerly p enac inhibitor discovered parion treatment pulmonary diseases including cf chronic obstructive pulmonary disease noncf bronchiectasis accordance terms agreement paid million upfront license fee recorded rd expenses consolidated statement income future alternative use technology made million investment parion form convertible debt recorded noncurrent assets consolidated balance sheet collaboration agreement lead development commercialization activities provide funding full time equivalent employees certain research activities addition obligated make additional payments upon achievement certain milestones pay royalties future net sales products developed approved relation collaboration august development gs terminated term research collaboration extended identify additional enac inhibitors development roche september entered development license agreement agreement roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation table contents gilead sciences inc notes consolidated financial statementscontinued treatment prevention influenza codeveloped us roche agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us percentage net revenues roche generates tamiflu sales turn subject reduction certain defined manufacturing costs november entered first amendment supplement agreement roche amended agreement provided formation joint manufacturing committee review roches manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis case consisting representatives roche us amended agreement also option provide specialized sales force supplement roches marketing efforts united states tamiflu royalties payable us net sales tamiflu sold roche remain amended agreement follows first million worldwide net sales given calendar year b next million worldwide net sales calendar year c worldwide net sales excess million calendar year amended agreement revised provision agreement relating calculation royalty payments given calendar quarter roche pay royalties based actual royalty rates applicable quarter addition amended agreement royalties payable roche us longer subject cost goods sold adjustment provided agreement recorded total million million million tamiflu royalties respectively result acquisition cv therapeutics april assumed rights agreement cv therapeutics roche exclusive worldwide license ranexa license agreement paid initial license fee obligated make certain payments roche upon receipt first second product approvals ranexa following major market countries france germany italy united states united kingdom january received fda approval ranexa treatment chronic angina paid million roche accordance agreement july received marketing authorization european medicines agency emea ranexa treatment chronic angina european union member states paid million roche related approval amount capitalized noncurrent asset consolidated balance sheet amortized useful patent life approximately years expiring september june entered amendment agreement roche related ranexa amendment provided us exclusive worldwide commercial rights ranexa potential indications humans terms amendment made upfront payment roche obligated make royalty payments roche worldwide net product sales licensed products addition obligated make additional milestone payments upon achievement certain regulatory approvals japan tobacco inc march japan tobacco inc japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor formerly known gs countries world excluding japan japan tobacco retained rights terms agreement incurred upfront license fee million included rd expenses future alternative use technology march recorded million rd expenses related table contents gilead sciences inc notes consolidated financial statementscontinued milestone incurred result dosing first patient phase clinical study july recorded million rd expenses related milestone paid related dosing first patient phase clinical study obligated make additional payments upon achievement milestones well pay royalties future product sales arising collaboration glaxosmithkline inc april granted gsk right commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territories agreement retained rights hepsera united states canada europe australia new zealand turkey gsk received exclusive rights develop hepsera solely treatment chronic hepatitis b territories significant include china japan south korea taiwan gsk full responsibility development commercialization hepsera territories terms agreement received upfront license payment million received aggregate million milestone payments related commercial approvals hepsera various countries received aggregate million milestone payments gsk achievement gsk four consecutive quarters hepsera gross sales exceeding million achievement certain drug status china upfront license fee milestone payments recorded deferred revenue total million million amortized contract revenue respectively first quarter terminated supply agreement gsk allow gsk assume manufacturing supply obligations hepsera use gsk territories result termination supply agreement recognized remaining million balance deferred revenue contract revenue march terms agreement gsk also required pay us royalties net sales gsk generates sales hepsera epivirhbvzeffix gsks hepatitis product gsk territories recorded million million million royalty revenues respectively november entered agreement gsk commercialize viread treatment chronic hepatitis b five countries asia agreement retain exclusive rights commercialization viread chronic hepatitis b hong kong singapore south korea taiwan china gsk exclusive commercialization rights viread chronic hepatitis b company pay royalties sales viread chronic hepatitis b respective asian territories september granted gsk exclusive right commercialize tenofovir disoproxil fumarate chronic hepatitis b japan gsk required pay us royalties sales tenofovir disoproxil fumarate chronic hepatitis b territory result acquisition myogen inc myogen november assumed rights march license distribution supply agreements myogen gsk terms license agreement gsk exclusive rights market ambrisentan active pharmaceutical ingredient letairis name volibris pah territories outside united states received upfront payment million subject achievement specific milestones eligible receive total additional milestone payments million addition receive royalties based net sales volibris gsk territories gsk option negotiate us exclusive sublicense additional therapeutic uses volibris gsk territories term license agreement continue conduct bear expense clinical development activities believe required obtain maintain regulatory approvals letairis volibris united states canada european economic area party may conduct additional development activities territories expense table contents gilead sciences inc notes consolidated financial statementscontinued parties may agree jointly develop ambrisentan new indications licensed field party pay share external costs associated joint development received milestone payment million gsk validation emea marketing authorization application volibris received million milestone payment related european commission marketing authorization approval volibris milestone front license payments recorded deferred revenue amortized contract revenue remaining period performance obligations agreement approximately six years amortized million million million contract revenue respectively astellas us llc astellas pharma us inc astellas applicable result acquisition cv therapeutics april assumed rights july collaboration agreement cv therapeutics astellas us llc develop market second generation pharmacologic mpi stress agents agreement astellas received exclusive north american rights lexiscan backup compound april received fda approval lexiscan use pharmacologic stress agent mpi studies patients unable undergo adequate exercise stress terms agreement product marketed astellas launched june united states years ended december recognized million million respectively royalty revenue astellas related sales lexiscan since agreement astellas pharma us inc related rights market ambisome terms agreement astellas responsible promotion ambisome united states canada exclusive marketing rights ambisome rest world subject obligation pay royalties astellas connection sales significant markets asia receive royalties astellas sales ambisome unites states canada connection agreement recorded royalty revenues million million million respectively tibotec pharmaceuticals july entered license collaboration agreement tibotec pharmaceuticals tibotec whollyowned subsidiary johnson johnson develop commercialize fixeddose combination truvada tibotecs nonnucleoside reverse transcriptase inhibitor tmc mg rilpivirine hydrochloride currently pending marketing application january received refuse file notification us fda communication fda requested additional information respect chemistry manufacturing controls section nda submission february refiled new drug application included requested information awaiting fdas response whether substantially complete permit substantive review license collaboration agreement tibotec granted exclusive license combination product administration adults oncedaily oral dosage form worldwide excluding developing world countries japan neither party restricted combining drug products drugs accordance terms agreement reimburse million approximately million development costs incurred tibotec tmc december required use commercially reasonable efforts develop formulate combination product including completion bioequivalence studies years ended december recorded million approximately million million approximately million respectively reimbursable rd expenses incurred tibotec development tmc tibotec required use commercially reasonable efforts develop tmc obtain approval united states europe table contents gilead sciences inc notes consolidated financial statementscontinued manufacture combination product assume lead role registration distribution subject regulatory approval commercialization combination product licensed countries tibotec right detail combination product licensed countries option request distributor combination product limited number countries price combination product expected sum prices truvada tmc components expect recognize product sales revenue future sales combination product approved cost tmc purchased us tibotec combination product approximate market price tmc less specified percentage thirty percent longterm obligations convertible senior notes following table summarizes carrying amount convertible senior notes thousands december convertible senior notes convertible senior notes convertible senior notes convertible senior notes total convertible senior notes net less current portion convertible senior notes total noncurrent convertible senior notes net notes april issued million convertible senior notes due notes million convertible senior notes due notes private placement pursuant rule securities act amended notes notes issued par bear interest rates respectively debt issuance costs million recorded noncurrent assets amortized interest expense contractual terms notes initial conversion rate notes shares per principal amount notes represents initial conversion price approximately per share initial conversion rate notes shares per principal amount notes represents initial conversion price approximately per share conversion rates subject customary anti dilution adjustments notes may converted subject adjustment following circumstances calendar quarter beginning september closing price common stock least trading days last consecutive trading day period previous quarter applicable conversion price per share make specified distributions holders common stock specified corporate transactions occur last month prior maturity applicable notes upon conversion holder would receive amount cash equal lesser principal amount note ii conversion value note conversion value exceeds principal amount may also deliver option cash common stock combination cash common stock conversion value excess principal amount notes converted connection change control may required provide make whole premium table contents gilead sciences inc notes consolidated financial statementscontinued form increase conversion rate subject stated maximum amount addition event change control holders may require us purchase portion notes purchase price equal principal amount plus accrued unpaid interest concurrent issuance notes purchased convertible note hedges private transactions cost million tax deductible life notes also sold warrants private transactions received net proceeds million sale warrants convertible note hedges warrants intended reduce potential economic dilution upon future conversions notes effectively increasing conversion price per share notes per share notes net cost million convertible note hedge warrant transactions recorded stockholders equity consolidated balance sheets convertible note hedges cover subject customary antidilution adjustments million shares common stock strike prices initially correspond initial conversion prices notes subject adjustments similar applicable conversion price related notes market value per share common stock time conversion notes strike price applicable convertible note hedges entitled receive counterparties transactions shares common stock extent made corresponding election respect related convertible notes cash combination cash shares common stock option excess market value common stock strike price convertible note hedges convertible note hedges terminate upon maturity notes none notes remain outstanding due conversion otherwise million shares common stock underlying warrants subject customary antidilution adjustments warrants strike prices per share warrants expiring per share warrants expiring exercisable respective expiration dates market value common stock time exercise applicable warrants exceeds respective strike prices required net settle cash shares common stock option respective counterparties value warrants excess warrant strike prices contemporaneously closing sale notes portion net proceeds notes issuance proceeds warrant transactions used repurchase million shares common stock million current accounting guidance bifurcated conversion option notes debt instrument classified conversion option equity accreting resulting debt discount interest expense following table summarizes information equity liability components notes thousands carrying value equity net carrying amount unamortized discount component liability component liability component december december december convertible senior notes convertible senior notes total convertible senior notes years ended december recognized million million million respectively interest expense related contractual coupon rates amortization table contents gilead sciences inc notes consolidated financial statementscontinued debt discount notes effective interest rates liability components notes respectively notes converted december ifconverted value would exceed principal amounts notes notes notes july issued billion convertible senior notes due notes billion convertible senior notes due notes private placement pursuant rule securities act amended notes issued par bear interest rates respectively debt issuance costs primarily comprised million bankers fees majority recorded noncurrent assets amortized interest expense contractual terms notes aggregate principal amount notes sold reflects full exercise initial purchasers option purchase additional notes cover overallotments initial conversion rate notes shares per principal amount represents initial conversion price approximately per share initial conversion rate notes shares per principal amount represents initial conversion price approximately per share conversion rates subject customary antidilution adjustments notes may converted prior april april respectively following circumstances calendar quarter commencing september closing price common stock least trading days whether consecutive period consecutive trading days ending last trading day preceding calendar quarter greater applicable conversion price applicable trading day five business day period measurement period ten consecutive trading days trading day period trading price per principal amount notes less product last reported sale price gilead common stock applicable conversion rate trading day upon occurrence specified corporate transactions distribution certain stock rights cash amounts assets gilead shareholders occurrence change control april case notes april case notes holders may convert notes time regardless foregoing circumstances generally upon conversion holder would receive amount cash equal lesser principal amount note ii conversion value note measured indenture governing relevant notes conversion value exceeds principal amount may also deliver option cash common stock combination cash common stock conversion value excess principal amount notes converted connection change control may required provide make whole premium form increase conversion rate subject stated maximum amount addition event change control holders may require us purchase portion notes purchase price equal principal amount plus accrued unpaid interest concurrent issuance notes purchased convertible note hedges private transactions cost million tax deductible life notes also sold warrants private transactions received net proceeds million sale warrants convertible note hedges warrants intended reduce potential economic dilution upon future conversions notes effectively increasing conversion price per share notes per share notes net cost million convertible note hedge warrant transactions recorded stockholders equity consolidated balance sheets convertible note hedges cover subject customary antidilution adjustments million shares common stock strike prices initially correspond initial conversion prices table contents gilead sciences inc notes consolidated financial statementscontinued notes subject adjustments similar applicable conversion price related notes market value per share common stock time conversion notes strike price applicable convertible note hedges entitled receive counterparties transactions shares common stock extent made corresponding election respect related convertible notes cash combination cash shares common stock option excess market value common stock strike price convertible note hedges convertible note hedges terminate upon maturity notes none notes remain outstanding due conversion otherwise million shares common stock underlying warrants subject customary antidilution adjustments warrants strike prices per share warrants expiring per share warrants expiring exercisable respective expiration dates market value common stock time exercise applicable warrants exceeds respective strike prices required net settle cash shares common stock option respective counterparties value warrants excess warrant strike prices used continue use net proceeds issuance convertible notes repurchase shares common stock repay existing indebtedness current accounting guidance bifurcated conversion option notes debt instrument classified conversion option equity accreting resulting debt discount interest expense following table summarizes information equity liability components notes thousands carrying value equity net carrying amount unamortized discount component liability component liability component december december december convertible senior notes convertible senior notes total convertible senior notes year ended december recognized million interest expense related contractual coupon rates amortization debt discount notes effective interest rate liability components notes respectively notes converted december ifconverted value would exceed principal amounts notes notes credit facility amended restated credit agreement along whollyowned subsidiary gilead biopharmaceutics ireland corporation may borrow aggregate billion revolving credit loans credit agreement also includes subfacility swingline loans letters credit loans credit agreement bear interest interest rate either libor plus margin ranging basis points basis points base rate described credit agreement may reduce commitments may prepay loans credit agreement whole part time without penalty subject certain conditions credit agreement terminate december unpaid borrowings thereunder shall due payable time april connection acquisition cv therapeutics borrowed million credit agreement partially fund acquisition december repaid table contents gilead sciences inc notes consolidated financial statementscontinued million credit agreement may borrowed million credit agreement fund stock repurchases august repaid million borrowed credit agreement using proceeds convertible senior notes issued july december million letters credit outstanding billion credit agreement required comply certain covenants credit agreement december compliance covenants commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities lease facilities foster city palo alto san dimas california durham north carolina boulder colorado seattle washington dublin cork areas ireland london area united kingdom also operating leases sales marketing administrative facilities europe canada asia pacific leases expire various dates many leases containing options renew certain facility leases also contain rent escalation clauses significant lease related facility seattle washington expires year term lease provides us three consecutive rights extend term lease contains annual three percent rent escalation clause lease also requires us pay additional amounts operating expenses maintenance also leases three corporate aircraft varying terms renewal options upon expiration lease terms lease expense operating leases approximately million million million years ended december respectively aggregate noncancelable future minimum rental payments operating leases follows thousands thereafter legal proceedings august received subpoena office inspector general us department health human services requesting documents regarding development marketing sales ranexa ranexa approved treatment chronic angina developed originally commercialized cv therapeutics company gilead acquired april following receipt subpoena cooperated governments inquiry december united states department justice notified united states district court northern district california decision intervene false claims act lawsuit filed former employee cv therapeutics regarding promotion ranexa december plaintiffrelator filed notice voluntary dismissal without prejudice underlying lawsuit united states consented dismissal without prejudice party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations table contents gilead sciences inc notes consolidated financial statementscontinued commitments normal course business enter various firm purchase commitments primarily related active pharmaceutical ingredients certain inventory related items december commitments next five years approximately million million million million million amounts related active pharmaceutical ingredients represent minimum purchase requirements actual payments purchases related active pharmaceutical ingredients million billion billion years ended december respectively stockholders equity stock repurchase programs october board authorized program repurchase common stock amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means including accelerated stock repurchase transactions similar arrangements repurchased retired shares common stock per share aggregate million billion stock repurchase program february entered accelerated share repurchase agreement financial institution repurchase million common stock accelerated basis terms accelerated share repurchase agreement paid million financial institution settle initial purchase transaction received shares common stock price per share june upon maturity agreement accordance share delivery provisions agreement received additional shares common stock based average daily volume weighted average prices common stock specified period less predetermined discount per share result average purchase price common stock accelerated share repurchase per share accounted accelerated share repurchase two separate transactions shares common stock acquired treasury stock transaction recorded transaction date b forward contract indexed common stock accounted shares received repurchase common stock retired shares immediately net income per share purposes additional shares received upon maturity contract june also recorded stockholders equity determined forward contract indexed common stock met applicable criteria equity classification therefore contract accounted derivative october entered accelerated share repurchase agreement financial institution repurchase million common stock accelerated basis terms accelerated share repurchase agreement paid million settle initial purchase transaction received shares common stock initial price per share march upon termination agreement accordance share delivery provisions agreement received additional shares common stock based average daily volume weightedaverage prices common stock specified period less predetermined discount per share result total number shares repurchased retired accelerated share repurchase agreement shares average purchase price per share accounting accelerated share repurchase consistent previous accelerated share repurchase table contents gilead sciences inc notes consolidated financial statementscontinued addition common stock repurchased two accelerated share repurchase transactions repurchased retired shares common stock average purchase price per share aggregate purchase price million open market transactions addition additional shares received accelerated share repurchase agreement completed march repurchased retired shares common stock average purchase price per share aggregate purchase price million open market transactions december completed share repurchases billion stock repurchase program january board authorized new program repurchase common stock amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means completed plan may time board authorized new threeyear billion stock repurchase program december repurchased billion common stock program december remaining authorized amount stock repurchases may made billion repurchase program billion utilized total billion repurchase retire million shares common stock average purchase price per share january board authorized additional threeyear billion stock repurchase program commence upon completion existing program authorized may use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated apic based estimated average sales price per issued share excess amounts charged retained earnings result stock repurchases reduced common stock apic aggregate million charged billion retained earnings result stock repurchases reduced common stock apic aggregate million charged million retained earnings result stock repurchases reduced common stock apic aggregate million charged billion retained earnings preferred stock shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series designated shares series junior participating preferred stock potential issuance november rights agreement bny mellon investor services llc formerly known chasemellon shareholder services llc amended rights plan preferred stock outstanding december rights plan rights plan provides distribution preferred stock purchase right dividend share common stock purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group common stock purchase rights permit holders holder purchase common stock discount market price time upon payment specified exercise price per purchase right addition event certain business combinations purchase rights permit purchase common stock acquirer table contents gilead sciences inc notes consolidated financial statementscontinued discount market price time certain conditions purchase rights may redeemed board whole part price per purchase right purchase rights voting privileges attached automatically trade common stock october october may board approved amendments rights plan first amendment provided among things increase exercise price right plan extension term plan november october second amendment provides among things increase exercise price right plan extension term rights plan october third amendment clarifying amendment entered connection increase designated number shares series junior participating preferred stock potential issuance rights plan may stock option plans may stockholders approved adopted gilead sciences inc equity incentive plan plan stock options nexstar pharmaceuticals inc nexstar triangle pharmaceuticals inc triangle corus myogen cv therapeutics stock option plans assumed result acquisitions nexstar triangle corus myogen cv therapeutics converted options purchase common stock effective closing respective acquisitions plan broad based incentive plan allows awards granted employees directors consultants plan provides option grants designated either nonqualified incentive stock options prior january granted non qualified incentive stock options stock options granted january nonqualified stock options plan employee stock options granted prior generally vest five years exercisable period exceed contractual term ten years date stock options issued granted prices less fair market value common stock grant date stock option exercises settled common stock plans previously authorized available pool shares connection acquisition cv therapeutics assumed cv therapeutics equity incentive plan amended restated nonemployee directors stock option plan amended restated equity incentive plan amended restated nonstatutory incentive plan amended restated employee commencement incentive plan amended restated collectively cv therapeutics plans majority options issued outstanding cv therapeutics plans april converted options purchase approximately million shares common stock remain subject original terms conditions shares available future grant cv therapeutics plans december total shares common stock authorized grant shares remain available future grant plan table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes activity stock option plans option grants presented table exercise prices less fair value underlying common stock grant date shares thousands year ended december weighted weighted weighted average average average shares exercise price shares exercise price shares exercise price outstanding beginning year granted assumed forfeited expired exercised outstanding end year exercisable end year weightedaverage grant date fair value options granted year total intrinsic value options exercised years ended december million million million respectively total fair value stock options vested years ended december million million million respectively december number options outstanding expected vest net estimated future option forfeitures weightedaverage exercise price per share aggregate intrinsic value million weightedaverage remaining contractual life years aggregate intrinsic value stock options outstanding stock options exercisable december million million respectively december weightedaverage remaining contractual life options outstanding options exercisable years respectively december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years performance shares restricted stock awards plan grant performancebased restricted stock awards vest upon achievement specified market performance goals relative predetermined peer group actual number common shares ultimately issued calculated multiplying number performance shares payout percentage ranging performance shares vest committee subcommittee board determined achieved specified market performance goals january granted performancebased share awards performance shares performance shares performance shares respectively awards vest single threeyear performance measurement vesting period performance share awards fair value performance share grant estimated grant date using monte carlo valuation methodology weightedaverage grant date fair values performance shares table contents gilead sciences inc notes consolidated financial statementscontinued per share respectively recognized million million million stockbased compensation expenses respectively related performance shares also granted performancebased restricted stock awards certain employees plan vesting awards subject achievement specified performance goals number awards issued date significant granted timebased restricted stock awards employees plan awards vest annually fiveyear period recognized million stockbased compensation expenses related timebased awards employee stock purchase plan employee stock purchase plan amended espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair market value common stock offering date purchase date espp offers twoyear lookback feature well automatic reset feature provides offering period reset new lower priced offering offering price new offering period less current offering period espp purchases settled common stock espps previously authorized available pool shares shares issued espp million total shares common stock reserved issuance espp shares available issuance espp december december million unrecognized compensation cost related espp expected recognized estimated weightedaverage period year stockbased compensation following table summarizes stockbased compensation expenses included consolidated statements income thousands year ended december cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense included net income years ended december capitalized million million million stockbased compensation costs inventory respectively stockbased compensation recognized expense requisite service periods consolidated statements income using graded vesting expense attribution approach unvested stock options granted prior january using straightline expense attribution approach stock options granted table contents gilead sciences inc notes consolidated financial statementscontinued adoption new guidance sharebased payments employees directors january stockbased compensation expenses related stock options recognized adoption new guidance based awards ultimately expected vest gross expense reduced estimated forfeitures guidance requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates estimated forfeitures based historical experience prior adoption guidance pro forma information required disclosed included forfeitures occurred result guidance adopted january recognize tax benefit stockbased compensation apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statements income rather apic valuation assumptions fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life used following assumptions calculate estimated fair value awards year ended december expected volatility stock options espp expected term years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted calculated using single option approach use blend historical volatility along implied volatility traded options common stock determine expected volatility expected term stockbased awards represents weightedaverage period awards expected remain outstanding estimate weightedaverage expected term based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts comprehensive income loss comprehensive income loss comprises net income certain changes stockholders equity excluded net income changes fair value outstanding effective cash flow hedges changes unrealized gains losses availableforsale securities changes cumulative foreign currency translation account comprehensive income loss years ended december table contents gilead sciences inc notes consolidated financial statementscontinued included consolidated statements stockholders equity components comprehensive income loss shown net related taxes underlying assets liabilities held jurisdictions expected generate future tax benefit liability following reclassifications recorded connection net realized gains losses sales securities cash flow hedges previously included comprehensive income loss thousands year ended december net unrealized gain loss related availableforsale securities net tax impact respectively net unrealized gain loss related cash flow hedges net tax impact respectively reclassification adjustments net tax impact respectively comprehensive income loss balance accumulated comprehensive income loss net taxes reported consolidated balance sheets consists following components thousands december net unrealized gain availableforsale securities net unrealized gain loss cash flow hedges cumulative foreign currency translation adjustment accumulated comprehensive income loss segment information operate one business segment primarily focuses development commercialization human therapeutics life threatening diseases products included one segment major products atripla truvada viread together accounted substantially total product sales years ended december similar economic characteristics including nature products production processes type customers distribution methods regulatory environment table contents gilead sciences inc notes consolidated financial statementscontinued product sales consist following thousands year ended december antiviral products atripla truvada viread hepsera emtriva total antiviral products ambisome letairis ranexa products total product sales following table summarizes total revenues external customers collaboration partners geographic region thousands product sales productrelated contract revenue attributed countries based shipto location royalty nonproduct related contract revenue attributed countries based location collaboration partner year ended december united states outside united states switzerland france spain united kingdom italy germany european countries countries total revenues outside united states total revenues following table summarizes revenues customers individually accounted total revenues total revenues year ended december cardinal health inc mckesson corp amerisourcebergen corp table contents gilead sciences inc notes consolidated financial statementscontinued december net book value property plant equipment united states ireland canada million million million respectively comprised approximately total net book value property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprised approximately total net book value property plant equipment income taxes provision income taxes consists following thousands year ended december federal current deferred state current deferred foreign current deferred provision income taxes foreign pretax income billion billion billion respectively cumulative unremitted foreign earnings considered permanently invested outside united states us taxes provided approximately billion billion december respectively residual us tax liability amounts remitted would approximately billion billion december respectively difference provision income taxes amount computed applying us federal statutory income tax rate income provision income taxes follows thousands year ended december income provision income taxes tax federal statutory rate state taxes net federal benefit foreign earnings different rates research credits net unbenefitted stock compensation provision income taxes table contents gilead sciences inc notes consolidated financial statementscontinued deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows thousands december deferred tax assets net operating loss carryforwards stockbased compensation reserves accruals currently deductible deferred revenue depreciation related research credit carryforwards capitalized intangibles net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities intangibles unremitted foreign earnings total deferred tax liabilities net deferred tax assets valuation allowance increased decreased million million million years ended december respectively concluded based standard set forth fasb accounting standards codification related income taxes likely realize benefit deferred tax assets related certain state net operating loss credit carryforwards december us federal net operating loss carryforwards approximately million federal net operating loss carryforwards start expire utilized also federal tax credit carryforwards approximately million start expire utilized addition state net operating loss tax credit carryforwards approximately billion million respectively state net operating loss tax credit carryforwards start expire respectively utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses nols credits utilization file federal state foreign income tax returns many jurisdictions united states abroad federal income tax purposes statute limitations open onwards certain acquired entities statute limitations open years inception due utilization nols credits carried prior years california income tax purposes statute limitations remains open onwards table contents gilead sciences inc notes consolidated financial statementscontinued income tax returns audited federal state foreign tax authorities currently examination internal revenue service irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions december total gross unrecognized tax benefits million million respectively total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition continued classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements income december accrued interest penalties related unrecognized tax benefits million million respectively december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification tax authorities around certain uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective tax authorities following rollforward total gross unrecognized tax benefit liabilities years ended december thousands december balance beginning period tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations balance end period deferred compensation plans maintain retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code gilead plan gilead plan employees may contribute eligible annual compensation subject irs plan limits make matching contributions gilead plan contributed employees contributions annual maximum match total matching contribution expense gilead plan years ended december million million million respectively maintain deferred compensation plan directors key employees may defer compensation income tax purposes deferred compensation plan nonqualified deferred compensation table contents gilead sciences inc notes consolidated financial statementscontinued plan subject qualification requirements section internal revenue code compensation deferred december subject requirements section internal revenue code plan officers senior grade level employees may contribute annual salaries annual bonus directors may contribute annual retainer fee amounts deferred participants deposited rabbi trust recorded noncurrent assets consolidated balance sheets beginning directors may also elect receive portion annual cash retainer phantom shares gives participant right receive amount equal value specified number shares specified period time payable shares common stock fractional shares paid cash established plan administrator december phantom shares outstanding participants elect one several distribution dates available plan receive deferred compensation payment subsequent events stock repurchase program january board authorized additional threeyear billion stock repurchase program commence upon completion existing program authorized may acquisition arresto biosciences inc december entered agreement acquire arresto biosciences inc arresto million plus potential future payments based achievement certain sales levels transaction closed january time arresto became whollyowned subsidiary arresto privately held developmentstage biotechnology company based palo alto california focused developing antibodies potential treatment fibrotic diseases cancer companys lead product gs formerly ab humanized monoclonal antibody mab targeting human lysyl oxidaselike loxl protein addition ongoing phase study gs patients advanced solid tumors phase study also initiated evaluate gs patients idiopathic pulmonary fibrosis believe arrestos pipeline research development expertise well aligned gileads areas focus given timing closing acquisition currently process valuing assets acquired liabilities assumed business combination result unable provide amounts recognized acquisition date major classes assets acquired liabilities assumed certain disclosures pertaining contingent consideration acquisition calistoga pharmaceuticals inc february entered agreement acquire calistoga pharmaceuticals inc calistoga million plus potential payments million based achievement certain milestones transaction expected close second quarter calistoga privatelyheld biotechnology company based seattle washington focused development medicines treat cancer inflammatory diseases company portfolio proprietary compounds selectively target isoforms phosphoinositide kinase pk calistogas lead product candidate cal firstin class specific inhibitor pk delta isoform pk delta preferentially expressed leukocytes involved variety inflammatory autoimmune diseases hematological cancers table contents gilead sciences inc notes consolidated financial statementscontinued quarterly results operations unaudited following amounts thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholdersbasic net income per share attributable gilead common stockholdersdiluted total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholdersbasic net income per share attributable gilead common stockholdersdiluted recorded million impairment charges rd expense related certain iprd assets acquired cv therapeutics see notes table contents gilead sciences inc schedule ii valuation qualifying accounts balance additions balance beginning charged end period expense deductions period year ended december accounts receivable allowances valuation allowance deferred tax assets year ended december accounts receivable allowances valuation allowance deferred tax assets year ended december accounts receivable allowances valuation allowance deferred tax assets allowances doubtful accounts sales returns cash discounts chargebacks valuation allowance deferred tax assets includes million million december respectively related acquisitions table contents